EP1141284A2 - Methodes permettant d'inhiber la croissance de cellules neoplasiques - Google Patents

Methodes permettant d'inhiber la croissance de cellules neoplasiques

Info

Publication number
EP1141284A2
EP1141284A2 EP99960644A EP99960644A EP1141284A2 EP 1141284 A2 EP1141284 A2 EP 1141284A2 EP 99960644 A EP99960644 A EP 99960644A EP 99960644 A EP99960644 A EP 99960644A EP 1141284 A2 EP1141284 A2 EP 1141284A2
Authority
EP
European Patent Office
Prior art keywords
seq
acid sequence
sequence identity
amino acid
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99960644A
Other languages
German (de)
English (en)
Inventor
Avi J. Ashkenazi
Audrey Goddard
Paul J. Godowski
Austin L. Gurney
Scot A. Marsters
Mary A. Napier
Robert M. Pitti
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/fr
Priority claimed from PCT/US1999/021547 external-priority patent/WO2000015797A2/fr
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/fr
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to EP04007617A priority Critical patent/EP1484338B1/fr
Priority to EP04007618A priority patent/EP1466977A1/fr
Priority to EP07001711A priority patent/EP1820859B9/fr
Priority to EP09004092A priority patent/EP2075335A3/fr
Publication of EP1141284A2 publication Critical patent/EP1141284A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Definitions

  • the present invention concerns methods and compositions for inhibiting neoplastic cell growth.
  • the present invention concerns antitumor compositions and methods for the treatment of tumors.
  • the invention further concerns screening methods for identifying growth inhibitory, e.g., antitumor compounds.
  • Malignant tumors are the second leading cause of death in the United States, after heart disease (Boring et al, CA Cancel J. Clin., 43:7 (1993)).
  • Cancer is characterized by the increase in the number of abnormal, or neoplastic, cells derived from a normal tissue which proliferate to form a tumor mass, the invasion of adjacent tissues by these neoplastic tumor cells, and the generation of malignant cells which eventually spread via the blood or lymphatic system to regional lymph nodes and to distant sites (metastasis). In a cancerous state a cell proliferates under conditions in which normal cells would not grow. Cancer manifests itself in a wide variety of forms, characterized by different degrees of invasiveness and aggressiveness.
  • neoplastic cells such as cancer cells.
  • the present invention relates to methods and compositions for inhibiting neoplastic cell growth. More particularly, the invention concerns methods and compositions for the treatment of tumors, including cancers, such as breast, prostate, colon, lung, ovarian, renal and CNS cancers, leukemia, melanoma, etc., in mammalian patients, preferably humans.
  • cancers such as breast, prostate, colon, lung, ovarian, renal and CNS cancers, leukemia, melanoma, etc.
  • the present invention concerns compositions of matter useful for the inhibition of neoplastic cell growth comprising an effective amount of a PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide as herein defined, or an agonist thereof, in admixture with a pharmaceutically acceptable carrier.
  • the composition of matter comprises a growth inhibitory amount of a PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide, or an agonist thereof.
  • the composition comprises a cytotoxic amount of a PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide, or an agonist thereof.
  • the compositions of matter may contain one or more additional growth inhibitory and/or cytotoxic and/or other chemotherapeutic agents.
  • the present invention concerns compositions of matter useful for the treatment of a tumor in a mammal comprising a therapeutically effective amount of a PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide as herein defined, or an agonist thereof.
  • the tumor is preferably a cancer.
  • the invention concerns a method for inhibiting the growth of a tumor cell comprising exposing the cell to an effective amount of a PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide as herein defined, or an agonist thereof.
  • the agonist is an anti-PR0179, anti-PRO207, anti-PRO320, anti-PR0219, anti- PR0221 , anti-PR0224, anti-PR0328, anti-PRO301 , anti-PR0526, anti-PR0362, anti-PR0356, anti-PRO509 or anti-PR0866 agonist antibody.
  • the agonist is a small molecule that mimics the biological activity of a PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide.
  • the method may be performed in vitro or in vivo.
  • the present invention provides an article of manufacture comprising: (a) a container; (b) a composition comprising an active agent contained within the container; wherein the composition is effective for inhibiting the neoplastic cell growth, e.g., growth of tumor cells, and the active agent in the composition is a PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide as herein defined, or an agonist thereof; and
  • a label affixed to said container, or a package insert included in said container referring to the use of said PROl 79, PRO207,PRO320,PRO219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide or agonist thereof, for the inhibition of neoplastic cell growth, wherein the agonist may be an antibody which binds to the PROl 79, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide.
  • the agonist is an anti-PR0179, anti-PRO207, anti-PRO320, anti-PR0219, anti-PR0221, anti-PR0224, anti-PR0328, anti- PRO301, anti-PR0526, anti-PR0362, anti-PR0356, anti-PRO509 or anti-PR0866 agonist antibody.
  • the agonist is a small molecule that mimics the biological activity of a PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide.
  • Similar articles of manufacture comprising a PROl 79, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide as herein defined, or an agonist thereof in an amount that is therapeutically effective for the treatment of tumor are also within the scope of the present invention. Also within the scope of the invention are articles of manufacture comprising a PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide as herein defined, or an agonist thereof, and a further growth inhibitory agent, cytotoxic agent or chemotherapeutic agent.
  • the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide.
  • the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% sequence identity, preferably at least about 81% sequence identity, more preferably at least about 82% sequence identity, yet more preferably at least about 83% sequence identity, yet more preferably at least about 84% sequence identity, yet more preferably at least about 85% sequence identity, yet more preferably at least about 86% sequence identity, yet more preferably at least about 87% sequence identity, yet more preferably at least about 88% sequence identity, yet more preferably at least about 89% sequence identity, yet more preferably at least about 90% sequence identity, yet more preferably at least about 91 % sequence identity, yet more preferably at least about 92% sequence identity, yet more preferably at least about 93% sequence identity, yet more preferably at least about 94% sequence identity, yet more preferably at least about 95% sequence identity, yet more preferably at least about 96% sequence identity, yet more preferably at least about 97% sequence identity, yet more preferably at least about 98% sequence identity and yet more preferably at least about 99% sequence identity
  • the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% sequence identity, preferably at least about 81% sequence identity, more preferably at least about 82% sequence identity, yet more preferably at least about 83% sequence identity, yet more preferably at least about 84% sequence identity, yet more preferably at least about 85% sequence identity, yet more preferably at least about 86% sequence identity, yet more preferably at least about 87% sequence identity, yet more preferably at least about 88% sequence identity, yet more preferably at least about 89% sequence identity, yet more preferably at least about 90% sequence identity, yet more preferably at least about 91 % sequence identity, yet more preferably at least about 92% sequence identity, yet more preferably at least about 93% sequence identity, yet more preferably at least about 94% sequence identity, yet more preferably at least about 95% sequence identity, yet more preferably at least about 96% sequence identity, yet more preferably at least about 97% sequence identity, yet more preferably at least about 98% sequence identity and yet more preferably at least about 99% sequence identity
  • the invention concerns an isolated nucleic acid molecule comprising a nucleotide sequence having at least about 80% sequence identity, preferably at least about 81% sequence identity, more preferably at least about 82% sequence identity, yet more preferably at least about 83% sequence identity, yet more preferably at least about 84% sequence identity, yet more preferably at least about 85% sequence identity, yet more preferably at least about 86% sequence identity, yet more preferably at least about 87% sequence identity, yet more preferably at least about 88% sequence identity, yet more preferably at least about 89% sequence identity, yet more preferably at least about 90% sequence identity, yet more preferably at least about 91 % sequence identity, yet more preferably at least about 92% sequence identity, yet more preferably at least about 93% sequence identity, yet more preferably at least about 94% sequence identity, yet more preferably at least about 95% sequence identity, yet more preferably at least about 96% sequence identity, yet more preferably at least about 97% sequence identity, yet more preferably at least about 98% sequence identity and yet more preferably at
  • Another aspect the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a PR0179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated, or is complementary to such encoding nucleotide sequence, wherein the transmembrane domain(s) of such polypeptide are disclosed herein.
  • soluble extracellular domains of the herein described PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptides are contemplated.
  • Another embodiment is directed to fragments of a PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide coding sequence, or the complement thereof, that may find use as, for example, hybridization probes, for encoding fragments of a PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide that may optionally encode a polypeptide comprising a binding site for an anti- PROl 79,anti-PRO207,anti-PRO320,anti-PRO219,anti-PR0221 , anti-PR0224, anti-PR0328, anti-PRO301 , anti- PR0526, anti-PR0362, anti-PR0356, anti-PRO509 or anti-PR0866 antibody or as antisense oligonucleotide probes.
  • nucleic acid fragments are usually at least about 20 nucleotides in length, preferably at least about 30 nucleotides in length, more preferably at least about 40 nucleotides in length, yet more preferably at least about 50 nucleotides in length, yet more preferably at least about 60 nucleotides in length, yet more preferably at least about 70 nucleotides in length, yet more preferably at least about 80 nucleotides in length, yet more preferably at least about 90 nucleotides in length, yet more preferably at least about 100 nucleotides in length, yet more preferably at least about 1 10 nucleotides in length, yet more preferably at least about 120 nucleotides in length, yet more preferably at least about 130 nucleotides in length, yet more preferably at least about 140 nucleotides in length, yet more preferably at least about 150 nucleotides in length, yet more preferably at least about 160 nucleotides in length, yet more preferably at least about 170 nucleo
  • novel fragments of a PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide-encoding nucleotide sequence may be determined in a routine manner by aligning the PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide-encoding nucleotide sequence with other known nucleotide sequences using any of a number of well known sequence alignment programs and determining which PR0179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide-encoding nucleotide sequence fragment(s) are novel.
  • PROl 79 PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide-encoding nucleotide sequences are contemplated herein.
  • PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide fragments encoded by these nucleotide molecule fragments preferably those PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide fragments that comprise a binding site for an anti-PR0179, anti-PRO207, anti-PRO320, anti-PR0219, anti-PR0221, anti-PR0224, anti- PR0328, anti-PRO301, anti-PR0526, anti-PR0362, anti-PR0356, anti-PRO509 or anti-PR0866 antibody.
  • the invention provides isolated PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
  • the invention concerns an isolated PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 81% sequence identity, more preferably at least about 82% sequence identity, yet more preferably at least about 83% sequence identity, yet more preferably at least about 84% sequence identity, yet more preferably at least about 85% sequence identity, yet more preferably at least about 86% sequence identity, yet more preferably at least about 87% sequence identity, yet more preferably at least about 88% sequence identity, yet more preferably at least about 89% sequence identity, yet more preferably at least about 90% sequence identity, yet more preferably at least about 91 % sequence identity, yet more preferably at least about 92% sequence identity, yet more preferably at least about 93% sequence identity, yet more preferably at least about 94% sequence identity, yet more preferably at least about 95% sequence
  • the invention concerns an isolated PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 81 % sequence identity, more preferably at least about 82% sequence identity, yet more preferably at least about 83% sequence identity, yet more preferably at least about 84% sequence identity, yet more preferably at least about 85% sequence identity, yet more preferably at least about 86% sequence identity, yet more preferably at least about 87% sequence identity, yet more preferably at least about 88% sequence identity, yet more preferably at least about 89% sequence identity, yet more preferably at least about 90% sequence identity, yet more preferably at least about 91 % sequence identity, yet more preferably at least about 92% sequence identity, yet more preferably at least about 93% sequence identity, yet more preferably at least about 94% sequence identity, yet more preferably at least about 95% sequence
  • the invention concerns an isolated PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 81 % positives, more preferably at least about 82% positives, yet more preferably at least about 83% positives, yet more preferably at least about 84% positives, yet more preferably at least about 85% positives, yet more preferably at least about 86% positives, yet more preferably at least about 87% positives, yet more preferably at least about 88% positives, yet more preferably at least about 89% positives, yet more preferably at least about 90% positives, yet more preferably at least about 91% positives, yet more preferably at least about 92% positives, yet more preferably at least about 93% positives, yet more preferably at least about 94% positives, yet more preferably at least about 95% positives,
  • the invention provides an isolated PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509or RO866polypeptide without the N-terminal signal sequence and/or the initiating methionine and is encoded by a nucleotide sequence that encodes such an amino acid sequence as hereinbefore described.
  • Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide and recovering the PR0179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide from the cell culture.
  • Another aspect of the invention provides an isolated PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated.
  • Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide and recovering the PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide from the cell culture.
  • the invention concerns agonists of a native PRO 179, PRO207, PRO320,
  • the agonist is an anti-PROl 79, anti-PRO207, anti-PRO320, anti- PR0219, anti-PR0221 , anti-PR0224, anti-PRO328,anti-PRO301 ,anti-PR0526,anti-PR0362,anti-PR0356, anti- PRO509 or anti-PR0866 agonist antibody or a small molecule.
  • the invention concerns a method of identifying agonists to a PRO 179, PRO207,
  • PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide which comprise contacting the PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide with a candidate molecule and monitoring a biological activity mediated by said PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide.
  • the PR0179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide is a native PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide.
  • the invention concerns a composition of matter comprising a PROl 79, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide, or an agonist of a PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide as herein described, or an anti-PROl 79, anti-PRO207, anti-PRO320, anti-PR0219, anti-PR0221 ,anti-PRO224,anti-PRO328,anti-PRO301 , anti-PR0526, anti-PR0362, anti-PR0356, anti-PRO509 or anti-PR0866 agonist antibody, in combination with a carrier.
  • the carrier is a pharmaceutically acceptable carrier.
  • Another embodiment of the present invention is directed to the use of a PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide, or an agonist thereof as hereinbefore described, or an anti-PROl 79, anti-PRO207, anti-PRO320, anti-PR0219, anti-PR0221 , anti-PR0224, anti-PR0328, anti-PRO301 ,anti-PR0526, anti-PR0362, anti-PR0356, anti-PRO509 or anti-PR0866 agonist antibody, for the preparation of a medicament useful in the treatment of a condition which is responsive to the PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide, an agonist thereof or an anti-PR0179, anti-PRO207, anti- PRO
  • the invention provides vectors comprising DNA encoding any of the herein described polypeptides.
  • Host cell comprising any such vector are also provided.
  • the host cells may be CHO cells, E. coli, yeast, or Baculovirus-infected insect cells.
  • a process for producing any of the herein described polypeptides is further provided and comprises culturing host cells under conditions suitable for expression of the desired polypeptide and recovering the desired polypeptide from the cell culture.
  • the invention provides chimeric molecules comprising any of the herein described polypeptides fused to a heterologous polypeptide or amino acid sequence.
  • Example of such chimeric molecules comprise any of the herein described polypeptides fused to an epitope tag sequence or a Fc region of an immunoglobulin.
  • the invention provides an antibody which specifically binds to any of the above or below described polypeptides.
  • the antibody is a monoclonal antibody, humanized antibody, antibody fragment or single-chain antibody.
  • the invention provides oligonucleotide probes useful for isolating genomic and cDNA nucleotide sequences or as antisense probes, wherein those probes may be derived from any of the above or below described nucleotide sequences.
  • Figure 1 shows the nucleotide sequence (SEQ ID NO: l) of a cDNA containing a nucleotide sequence encoding native sequence PROl 79, wherein the nucleotide sequence (SEQ ID NO: 1) is a clone designated herein as DNA 16451-1078. Also presented in bold font and underlined are the positions of the respective start and stop codons.
  • Figure 2 shows the amino acid sequence (SEQ ID NO:2) of a native sequence PROl 79 polypeptide as derived from the coding sequence of SEQ ID NO: 1 shown in Figure 1.
  • Figure 3 shows the nucleotide sequence (SEQ ID NO:6) of a cDNA containing a nucleotide sequence encoding native sequence PRO207, wherein the nucleotide sequence (SEQ ID NO:6) is a clone designated herein as DNA30879-1 152. Also presented in bold font and underlined are the positions of the respective start and stop codons.
  • Figure 4 shows the amino acid sequence (SEQ ID NO:7) of a native sequence PRO207 polypeptide as derived from the coding sequence of SEQ ID NO:6 shown in Figure 3.
  • Figure 5 shows the nucleotide sequence (SEQ ID NO:9) of a cDNA containing a nucleotide sequence encoding native sequence PRO320, wherein the nucleotide sequence (SEQ ID NO:9) is a clone designated herein as DNA32284-1307. Also presented in bold font and underlined are the positions of the respective start and stop codons.
  • Figure 6 shows the amino acid sequence (SEQ ID NO:10) of a native sequence PRO320 polypeptide as derived from the coding sequence of SEQ ID NO:9 shown in Figure 5.
  • Figure 7 shows the nucleotide sequence (SEQ ID NO: 14) of a cDNA containing a nucleotide sequence encoding native sequence PR0219, wherein the nucleotide sequence (SEQ ID NO: 14) is a clone designated herein as DNA32290-1 164. Also presented in bold font and underlined are the positions of the respective start and stop codons.
  • Figure 8 shows the amino acid sequence (SEQ ID NO: 15) of a native sequence PR0219 polypeptide as derived from the coding sequence of SEQ ID NO: 14 shown in Figure 7.
  • Figure 9 shows the nucleotide sequence (SEQ ID NO: 19) of a cDNA containing a nucleotide sequence encoding native sequence PR0221 , wherein the nucleotide sequence (SEQ ID NO: 19) is a clone designated herein as DNA33089-1 132. Also presented in bold font and underlined are the positions of the respective start and stop codons.
  • Figure 10 shows the amino acid sequence (SEQ ID NO:20) of a native sequence PR0221 polypeptide as derived from the coding sequence of SEQ ID NO: 19 shown in Figure 9.
  • Figure 1 1 shows the nucleotide sequence (SEQ ID NO:24) of a cDNA containing a nucleotide sequence encoding native sequence PR0224, wherein the nucleotide sequence (SEQ ID NO:24) is a clone designated herein as DNA33221-1133. Also presented in bold font and underlined are the positions of the respective start and stop codons.
  • Figure 12 shows the amino acid sequence (SEQ ID NO:25) of a native sequence PR0224 polypeptide as derived from the coding sequence of SEQ ID NO:24 shown in Figure 1 1.
  • Figure 13 shows the nucleotide sequence (SEQ ID NO:29) of a cDNA containing a nucleotide sequence encoding native sequence PR0328, wherein the nucleotide sequence (SEQ ID NO:29) is a clone designated herein as DNA40587-1231. Also presented in bold font and underlined are the positions of the respective start and stop codons.
  • Figure 14 shows the amino acid sequence (SEQ ID NO:30) of a native sequence PR0328 polypeptide as derived from the coding sequence of SEQ ID NO:29 shown in Figure 13.
  • Figure 15 shows the nucleotide sequence (SEQ ID NO:34) of a cDNA containing a nucleotide sequence encoding native sequence PRO301 , wherein the nucleotide sequence (SEQ ID NO:34) is a clone designated herein as DNA40628-1216. Also presented in bold font and underlined are the positions of the respective start and stop codons.
  • Figure 16 shows the amino acid sequence (SEQ ID NO:35) of a native sequence PRO301 polypeptide as derived from the coding sequence of SEQ ID NO:34 shown in Figure 15.
  • Figure 17 shows the nucleotide sequence (SEQ ID NO:42) of a cDNA containing a nucleotide sequence encoding native sequence PR0526, wherein the nucleotide sequence (SEQ ID NO:42) is a clone designated herein as DN A44184- 1319. Also presented in bold font and underlined are the positions of the respective start and stop codons.
  • Figure 18 shows the amino acid sequence (SEQ ID NO:43) of a native sequence PR0526 polypeptide as derived from the coding sequence of SEQ ID NO:42 shown in Figure 17.
  • Figure 19 shows the nucleotide sequence (SEQ ID NO:47) of a cDNA containing a nucleotide sequence encoding native sequence PR0362, wherein the nucleotide sequence (SEQ ID NO:47) is a clone designated herein as DNA45416-1251. Also presented in bold font and underlined are the positions of the respective start and stop codons.
  • Figure 20 shows the amino acid sequence (SEQ ID NO:48) of a native sequence PR0362 polypeptide as derived from the coding sequence of SEQ ID NO:47 shown in Figure 19.
  • Figure 21 shows the nucleotide sequence (SEQ ID NO:54) of a cDNA containing a nucleotide sequence encoding native sequence PR0356, wherein the nucleotide sequence (SEQ ID NO:54) is a clone designated herein as DNA47470-1 130-P1. Also presented in bold font and underlined are the positions of the respective start and stop codons.
  • Figure 22 shows the amino acid sequence (SEQ ID NO:55) of a native sequence PR0356 polypeptide as derived from the coding sequence of SEQ ID NO:54 shown in Figure 21.
  • Figure 23 shows the nucleotide sequence (SEQ ID NO:59) of a cDNA containing a nucleotide sequence encoding native sequence PRO509, wherein the nucleotide sequence (SEQ ID NO:59) is a clone designated herein as DNA50148- 1068. Also presented in bold font and underlined are the positions of the respective start and stop codons.
  • Figure 24 shows the amino acid sequence (SEQ ID NO:60) of a native sequence PRO509 polypeptide as derived from the coding sequence of SEQ ID NO:59 shown in Figure 23.
  • Figure 25 shows the nucleotide sequence (SEQ ID NO:61) of a cDNA containing a nucleotide sequence encoding native sequence PR0866, wherein the nucleotide sequence (SEQ ID NO:61 ) is a clone designated herein as DNA53971-1359. Also presented in bold font and underlined are the positions of the respective start and stop codons.
  • Figure 26 shows the amino acid sequence (SEQ ID NO:62) of a native sequence PR0866 polypeptide as derived from the coding sequence of SEQ ID NO:61 shown in Figure 25.
  • PRO179”, “PRO207”, “PRO320”, “PRO219”, “PRO221 “,”PRO224”,”PRO328”,”PRO301 “, "PR0526”, “PR0362”, “PR0356”, “PRO509” or “PRO866” polypeptide or protein when used herein encompass native sequence PROl 79, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 and PRO866 polypeptides and PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 and PR0866 variants (which are further defined herein).
  • PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant and/or synthetic methods.
  • a “native sequence PRO 179", “native sequence PRO207”, “native sequence PRO320”, “native sequence PR0219”, “native sequence PR0221 “, “native sequence PR0224”, “native sequence PR0328”, “native sequence PRO301 “, “native sequence PR0526”, “native sequence PR0362”, “native sequence PR0356”, “native sequence PRO509”, or “native sequence PR0866” comprises a polypeptide having the same amino acid sequence as the PR0179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide as derived from nature.
  • Such native sequence PROl 79, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide can be isolated from nature or can be produced by recombinant and/or synthetic means.
  • the term "native sequence" PR0179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 specifically encompasses naturally-occurringtruncated or secreted forms (e.g.
  • PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 and PRO866 polypeptides are naturally-occurring variant forms (e.g., alternatively spliced forms) and naturally-occurring allelic variants of the PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 and PRO866 polypeptides.
  • the native sequence PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide is a mature or full-length native sequence PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide as shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:7), Figure 6 (SEQ ID NO: 10), Figure 8 (SEQ ID N0:15), Figure 10 (SEQ ID NO:20), Figure 12 (SEQ ID NO:25), Figure 14 (SEQ ID NO:30), Figure 16 (SEQ ID NO:35), Figure 18 (SEQ ID NO:43), Figure 20 (SEQ ID NO:48), Figure 22 (SEQ ID NO:55), Figure 24 (SEQ ID NO:60) or Figure 26 (SEQ ID NO:
  • extracellular domain or "ECD” of a polypeptide disclosed herein refers to a form of the polypeptide which is essentially free of the transmembrane and cytoplasmic domains.
  • a polypeptide ECD will have less than about 1% of such transmembrane and/or cytoplasmic domains and preferably, will have less than about 0.5% of such domains. It will be understood that any transmembrane domain(s) identified for the polypeptides of the present invention are identified pursuant to criteria routinely employed in the art for identifying that type of hydrophobic domain.
  • the extracellular domain of a polypeptide of the present invention comprises amino acids 1 to X of the mature amino acid sequence, wherein X is any amino acid within 5 amino acids on either side of the extracellular domain/transmembrane domain boundary.
  • cleavage of a signal sequence from a secreted polypeptide is not entirely uniform, resulting in more than one secreted species.
  • These mature polypeptides, where the signal peptide is cleaved within no more than about 5 amino acids on either side of the C-terminal boundary of the signal peptide as identified herein, and the polynucleotides encoding them, are contemplated by the present invention.
  • PRO 179 variant polypeptide means an active PRO 179 polypeptide (other than a native sequence PRO 179 polypeptide) as defined below, having at least about 80% amino acid sequence identity with the amino acid sequence of (a) residues 1 or about 17 to 460 of the PRO 179 polypeptide shown in Figure 2 (SEQ ID NO:2), (b) X to 460 of the PROl 79 polypeptide shown in Figure 2 (SEQ ID NO:2), wherein X is any amino acid residue from 12 to 21 of Figure 2 (SEQ ID NO:2), or (c) another specifically derived fragment of the amino acid sequence shown in Figure 2 (SEQ ID NO:2).
  • PRO207 variant polypeptide means an active PRO207 polypeptide (other than a native sequence PRO207 polypeptide) as defined below, having at least about 80% amino acid sequence identity with the amino acid sequence of (a) residues 1 or about 41 to 249 of the PRO207 polypeptide shown in Figure 4 (SEQ ID NO:7), (b) X to 249 of the PRO207 polypeptide shown in Figure 4 (SEQ ID NO:7), wherein X is any amino acid residue from 36 to 45 of Figure 4 (SEQ ID NO:7), or (c) another specifically derived fragment of the amino acid sequence shown in Figure 4 (SEQ ID NO:7).
  • PRO320 variant polypeptide means an active PRO320 polypeptide (other than a native sequence PRO320 polypeptide) as defined below, having at least about 80% amino acid sequence identity with the amino acid sequence of (a) residues 1 or about 22 to 338 of the PRO320 polypeptide shown in Figure 6 (SEQ ID NO: 10), (b) X to 338 of the PRO320 polypeptide shown in Figure 6 (SEQ ID NO: 10), wherein X is any amino acid residue from 17 to 26 of Figure 6 (SEQ ID NO: 10), or (c) another specifically derived fragment of the amino acid sequence shown in Figure 6 (SEQ ID NO: 10).
  • PR0219 variant polypeptide means an active PR0219 polypeptide (other than a native sequence PR0219 polypeptide) as defined below, having at least about 80% amino acid sequence identity with the amino acid sequence of (a) residues 1 or about 24 to 1005 of the PR0219 polypeptide shown in Figure 8 (SEQ ID NO: 15), (b) X to 1005 of the PR0219 polypeptide shown in Figure 8 (SEQ ID NO: 15), wherein X is any amino acid residue from 19 to 28 of Figure 8 (SEQ ID NO: 15), or (c) another specifically derived fragment of the amino acid sequence shown in Figure 8 (SEQ ID NO: 15).
  • PR0221 variant polypeptide means an active PR0221 polypeptide (other than a native sequence PR0221 polypeptide) as defined below, having at least about 80% amino acid sequence identity with the amino acid sequence of (a) residues 1 or about 34 to 259 of the PR0221 polypeptide shown in Figure 10 (SEQ ID NO:20), (b)X to259 ofthe PR0221 polypeptide shown in Figure 10 (SEQ ID NO:20), wherein X is any amino acid residue from 29 to 38 of Figure 10 (SEQ ID NO:20), (c) 1 or about 34 to X of Figure 10 (SEQ ID NO:20), wherein X is any amino acid from amino acid 199 to amino acid 208 of Figure 10 (SEQ ID NO:20), or (d) another specifically derived fragment of the amino acid sequence shown in Figure 10 (SEQ ID NO:20).
  • PR0224 variant polypeptide means an active PR0224 polypeptide (other than a native sequence PR0224 polypeptide) as defined below, having at least about 80% amino acid sequence identity with the amino acid sequence of (a) residues 1 or about 31 to 282 of the PR0224 polypeptide shown in Figure 12 (SEQ ID NO:25), (b) X to 282 of the PR0224 polypeptide shown in Figure 12 (SEQ ID NO:25), wherein X is any amino acid residue from 26 to 35 of Figure 12 (SEQ ID NO:25), (c) 1 or about 31 to X of Figure 12 (SEQ ID NO:25), wherein X is any amino acid from amino acid 226 to amino acid 235 of Figure 12 (SEQ ID NO:25), or (d) another specifically derived fragment of the amino acid sequence shown in Figure 12 (SEQ ID NO:25).
  • PR0328 variant polypeptide means an active PR0328 polypeptide (other than a native sequence PR0328 polypeptide) as defined below, having at least about 80% amino acid sequence identity with the amino acid sequence of (a) residues 1 or about 23 to 463 of the PR0328 polypeptide shown in Figure 14 (SEQ ID NO:30), (b) X to 463 of the PR0328 polypeptide shown in Figure 14 (SEQ ID NO:30), wherein X is any amino acid residue from 18 to 27 of Figure 14 (SEQ ID NO:30), or (c) another specifically derived fragment of the amino acid sequence shown in Figure 14 (SEQ ID NO:30).
  • PRO301 variant polypeptide means an active PRO301 polypeptide (other than a native sequence PRO301 polypeptide) as defined below, having at least about 80% amino acid sequence identity with the amino acid sequence of (a) residues 1 or about 28 to 299 of the PRO301 polypeptide shown in Figure 16 (SEQ ID NO:35), (b)Xto 299 ofthe PRO301 polypeptide shown in Figure 16 (SEQ ID NO:35), wherein X is any amino acid residue from 23 to 32 of Figure 16 (SEQ ID NO:35), (c) 1 or about 28 to X of Figure 16 (SEQ ID NO:35), wherein X is any amino acid from amino acid 230 to amino acid 239 of Figure 16 (SEQ ID NO:35), or (d) another specifically derived fragment of the amino acid sequence shown in Figure 16 (SEQ ID NO:35).
  • PR0526 variant polypeptide means an active PR0526 polypeptide (other than a native sequence PR0526 polypeptide) as defined below, having at least about 80% amino acid sequence identity with the amino acid sequence of (a) residues 1 or about 27 to 473 of the PR0526 polypeptide shown in Figure 18 (SEQ ID NO:43), (b) X to 473 of the PR0526 polypeptide shown in Figure 18 (SEQ ID NO:43), wherein X is any amino acid residue from 22 to 31 of Figure 18 (SEQ ID NO:43), or (c) another specifically derived fragment of the amino acid sequence shown in Figure 18 (SEQ ID NO:43).
  • PR0362 variant polypeptide means an active PR0362 polypeptide (other than a native sequence PR0362 polypeptide) as defined below, having at least about 80% amino acid sequence identity with the amino acid sequence of (a) residues 1 or about 20 to 321 of the PR0362 polypeptide shown in Figure 20 (SEQ ID NO:48), (b) X to 321 of the PR0362 polypeptide shown in Figure 20 (SEQ ID NO:48), wherein X is any amino acid residue from 15 to 24 of Figure 20 (SEQ ID NO:48), (c) 1 or about 20 to X of Figure 20 (SEQ ID NO:48), wherein X is any' amino acid from amino acid 276 to amino acid 285 of Figure 20 (SEQ ID NO:48), or (d) another specifically derived fragment of the amino acid sequence shown in Figure 20 (SEQ ID NO:48).
  • PR0356 variant polypeptide means an active PR0356 polypeptide (other than a native sequence PR0356 polypeptide) as defined below, having at least about 80% amino acid sequence identity with the amino acid sequence of (a) residues 1 or about 27 to 346 of the PR0356 polypeptide shown in Figure 22 (SEQ ID NO:55), (b) X to 346 of the PR0356 polypeptide shown in Figure 22 (SEQ ID NO:55), wherein X is any amino acid residue from 22 to 31 of Figure 22 (SEQ ID NO:55), or (c) another specifically derived fragment of the amino acid sequence shown in Figure 22 (SEQ ID NO:55).
  • PRO509 variant polypeptide means an active PRO509 polypeptide (other than a native sequence
  • PRO509 polypeptide as defined below, having at least about 80% amino acid sequence identity with the amino acid sequence of (a) residues 1 or about 37 to 283 of the PRO509 polypeptide shown in Figure 24 (SEQ ID NO:60), (b) X to 283 of the PRO509 polypeptide shown in Figure 24 (SEQ ID NO:60), wherein X is any amino acid residue from 32 to 41 of Figure 24 (SEQ ID NO:60), (c) 1 or about 37 to X of Figure 24 (SEQ ID NO:60), wherein X is any amino acid from amino acid 200 to amino acid 209 of Figure 24 (SEQ ID NO:60), or (d) another specifically derived fragment of the amino acid sequence shown in Figure 24 (SEQ ID NO:60).
  • PR0866 variant polypeptide means an active PRO866 polypeptide (other than a native sequence PR0866 polypeptide) as defined below, having at least about 80% amino acid sequence identity with the amino acid sequence of (a) residues 1 or about 27 to 331 of the PRO866 polypeptide shown in Figure 26 (SEQ ID NO:62), (b) X to 331 of the PRO866 polypeptide shown in Figure 26 (SEQ ID NO:62), wherein X is any amino acid residue from 22 to 31 of Figure 26 (SEQ ID NO:62), or (c) another specifically derived fragment of the amino acid sequence shown in Figure 26 (SEQ ID NO:62).
  • PR0179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 and PRO866 variants include, for instance, PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 and PR0866 polypeptides wherein one or more amino acid residues are added, or deleted, at the N- or C-terminus, as well as within one or more internal domains of the native sequence.
  • a PRO 179 variant will have at least about 80% amino acid sequence identity, more preferably at least about 81% amino acid sequence identity, more preferably at least about 82% amino acid sequence identity, more preferably at least about 83% amino acid sequence identity, more preferably at least about 84% amino acid sequence identity, more preferably at least about 85% amino acid sequence identity, more preferably at least about 86% amino acid sequence identity, more preferably at least about 87% amino acid sequence identity, more preferably at least about 88% amino acid sequence identity, more preferably at least about 89% amino acid sequence identity, more preferably at least about 90% amino acid sequence identity, more preferably at least about 91% amino acid sequence identity, more preferably at least about 92% amino acid sequence identity, more preferably at least about 93% amino acid sequence identity, more preferably at least about 94% amino acid sequence identity, more preferably at least about 95% amino acid sequence identity, more preferably at least about 96% amino acid sequence identity, more preferably at least about 97% amino acid sequence identity, more preferably at least about 98% amino acid sequence identity and
  • a PRO207 variant will have at least about 80% amino acid sequence identity, more preferably at least about 81% amino acid sequence identity, more preferably at least about 82% amino acid sequence identity, more preferably at least about 83% amino acid sequence identity, more preferably at least about 84% amino acid sequence identity, more preferably at least about 85% amino acid sequence identity, more preferably at least about 86% amino acid sequence identity, more preferably at least about 87% amino acid sequence identity, more preferably at least about 88% amino acid sequence identity, more preferably at least about 89% amino acid sequence identity, more preferably at least about 90% amino acid sequence identity, more preferably at least about 91% amino acid sequence identity, more preferably at least about 92% amino acid sequence identity, more preferably at least about 93% amino acid sequence identity, more preferably at least about 94% amino acid sequence identity, more preferably at least about 95% amino acid sequence identity, more preferably at least about 96% amino acid sequence identity, more preferably at least about 97% amino acid sequence identity, more preferably at least about 98% amino acid sequence identity and yet
  • a PRO320 variant will have at least about 80% amino acid sequence identity, more preferably at least about 81% amino acid sequence identity, more preferably at least about 82% amino acid sequence identity, more preferably at least about 83% amino acid sequence identity, more preferably at least about 84% amino acid sequence identity, more preferably at least about 85% amino acid sequence identity, more preferably at least about 86% amino acid sequence identity, more preferably at least about 87% amino acid sequence identity, more preferably at least about 88% amino acid sequence identity, more preferably at least about 89% amino acid sequence identity, more preferably at least about 90% amino acid sequence identity, more preferably at least about 91%) amino acid sequence identity, more preferably at least about 92% amino acid sequence identity, more preferably at least about 93% amino acid sequence identity, more preferably at least about 94% amino acid sequence identity, more preferably at least about 95% amino acid sequence identity, more preferably at least about 96%> amino acid sequence identity, more preferably at least about 97% amino acid sequence identity, more preferably at least about 98% amino acid sequence identity
  • a PR0219 variant will have at least about 80% amino acid sequence identity, more preferably at least about 81 % amino acid sequence identity, more preferably at least about 82% amino acid sequence identity, more preferably at least about 83% amino acid sequence identity, more preferably at least about 84% amino acid sequence identity, more preferably at least about 85% amino acid sequence identity, more preferably at least about 86% amino acid sequence identity, more preferably at least about 87% amino acid sequence identity, more preferably at least about 88% amino acid sequence identity, more preferably at least about 89% amino acid sequence identity, more preferably at least about 90% amino acid sequence identity, more preferably at least about 91% amino acid sequence identity, more preferably at least about 92% amino acid sequence identity, more preferably at least about 93% amino acid sequence identity, more preferably at least about 94% amino acid sequence identity, more preferably at least about 95% amino acid sequence identity, more preferably at least about 96% amino acid sequence identity, more preferably at least about 97% amino acid sequence identity, more preferably at least about 98% amino acid sequence
  • a PR0221 variant will have at least about 80% amino acid sequence identity, more preferably at least about 81% amino acid sequence identity, more preferably at least about 82% amino acid sequence identity, more preferably at least about 83% amino acid sequence identity, more preferably at least about 84% amino acid sequence identity, more preferably at least about 85% amino acid sequence identity, more preferably at least about 86% amino acid sequence identity, more preferably at least about 87% amino acid sequence identity, more preferably at least about 88% amino acid sequence identity, more preferably at least about 89% amino acid sequence identity, more preferably at least about 90% amino acid sequence identity, more preferably at least about 91% amino acid sequence identity, more preferably at least about 92% amino acid sequence identity, more preferably at least about 93% amino acid sequence identity, more preferably at least about 94% amino acid sequence identity, more preferably at least about 95% amino acid sequence identity, more preferably at least about 96% amino acid sequence identity, more preferably at least about 97% amino acid sequence identity, more preferably at least about 98% amino acid sequence identity and
  • a PR0224 variant will have at least about 80% amino acid sequence identity, more preferably at least about 81% amino acid sequence identity, more preferably at least about 82% amino acid sequence identity, more preferably at least about 83% amino acid sequence identity, more preferably at least about 84% amino acid sequence identity, more preferably at least about 85% amino acid sequence identity, more preferably at least about 86% amino acid sequence identity, more preferably at least about 87% amino acid sequence identity, more preferably at least about 88% amino acid sequence identity, more preferably at least about 89% amino acid sequence identity, more preferably at least about 90% amino acid sequence identity, more preferably at least about 91% amino acid sequence identity, more preferably at least about 92% amino acid sequence identity, more preferably at least about 93% amino acid sequence identity, more preferably at least about 94% amino acid sequence identity, more preferably at least about 95% amino acid sequence identity, more preferably at least about 96% amino acid sequence identity, more preferably at least about 97% amino acid sequence identity, more preferably at least about 98% amino acid sequence identity and
  • a PR0328 variant will have at least about 80% amino acid sequence identity, more preferably at least about 81 % amino acid sequence identity, more preferably at least about 82% amino acid sequence identity, more preferably at least about 83% amino acid sequence identity, more preferably at least about 84% amino acid sequence identity, more preferably at least about 85% amino acid sequence identity, more preferably at least about 86% amino acid sequence identity, more preferably at least about 87% amino acid sequence identity, more preferably at least about 88% amino acid sequence identity, more preferably at least about 89% amino acid sequence identity, more preferably at least about 90% amino acid sequence identity, more preferably at least about 91% amino acid sequence identity, more preferably at least about 92% amino acid sequence identity, more preferably at least about 93% amino acid sequence identity, more preferably at least about 94% amino acid sequence identity, more preferably at least about 95% amino acid sequence identity, more preferably at least about 96% amino acid sequence identity, more preferably at least about 97% amino acid sequence identity, more preferably at least about 98% amino acid sequence
  • a PRO301 variant will have at least about 80% amino acid sequence identity, more preferably at least about 81 % amino acid sequence identity, more preferably at least about 82% amino acid sequence identity, more preferably at least about 83% amino acid sequence identity, more preferably at least about 84% amino acid sequence identity, more preferably at least about 85% a ino acid sequence identity, more preferably at least about 86% amino acid sequence identity, more preferably at least about 87% amino acid sequence identity, more preferably at least about 88% amino acid sequence identity, more preferably at least about 89% amino acid sequence identity, more preferably at least about 90% amino acid sequence identity, more preferably at least about 91 % amino acid sequence identity, more preferably at least about 92% amino acid sequence identity, more preferably at least about 93% amino acid sequence identity, more preferably at least about 94% amino acid sequence identity, more preferably at least about 95% amino acid sequence identity, more preferably at least about 96% amino acid sequence identity, more preferably at least about 97% amino acid sequence identity, more preferably at least about 9
  • a PR0526 variant will have at least about 80% amino acid sequence identity, more preferably at least about 81 % amino acid sequence identity, more preferably at least about 82% amino acid sequence identity, more preferably at least about 83% amino acid sequence identity, more preferably at least about 84% amino acid sequence identity, more preferably at least about 85% amino acid sequence identity, more preferably at least about 86% amino acid sequence identity, more preferably at least about 87% amino acid sequence identity, more preferably at least about 88% amino acid sequence identity, more preferably at least about 89% amino acid sequence identity, more preferably at least about 90% amino acid sequence identity, more preferably at least about 91% amino acid sequence identity, more preferably at least about 92% amino acid sequence identity, more preferably at least about 93% amino acid sequence identity, more preferably at least about 94% amino acid sequence identity, more preferably at least about 95% amino acid sequence identity, more preferably at least about 96% amino acid sequence identity, more preferably at least about 97% amino acid sequence identity, more preferably at least about 98% amino acid sequence
  • a PR0362 variant will have at least about 80% amino acid sequence identity, more preferably at least about 81 % amino acid sequence identity, more preferably at least about 82% amino acid sequence identity, more preferably at least about 83% amino acid sequence identity, more preferably at least about 84% amino acid sequence identity, more preferably at least about 85% amino acid sequence identity, more preferably at least about 86% amino acid sequence identity, more preferably at least about 87% amino acid sequence identity, more preferably at least about 88% amino acid sequence identity, more preferably at least about 89% amino acid sequence identity, more preferably at least about 90% amino acid sequence identity, more preferably at least about 91% amino acid sequence identity, more preferably at least about 92% amino acid sequence identity, more preferably at least about 93% amino acid sequence identity, more preferably at least about 94% amino acid sequence identity, more preferably at least about 95% amino acid sequence identity, more preferably at least about 96% amino acid sequence identity, more preferably at least about 97% amino acid sequence identity, more preferably at least about 98% amino acid sequence
  • a PR0356 variant will have at least about 80% amino acid sequence identity, more preferably at least about 81% amino acid sequence identity, more preferably at least about 82% amino acid sequence identity, more preferably at least about 83% amino acid sequence identity, more preferably at least about 84% amino acid sequence identity, more preferably at least about 85% amino acid sequence identity, more preferably at least about 86% amino acid sequence identity, more preferably at least about 87% amino acid sequence identity, more preferably at least about 88% amino acid sequence identity, more preferably at least about 89% amino acid sequence identity, more preferably at least about 90% amino acid sequence identity, more preferably at least about 91% amino acid sequence identity, more preferably at least about 92% amino acid sequence identity, more preferably at least about 93% amino acid sequence identity, more preferably at least about 94% amino acid sequence identity, more preferably at least about 95% amino acid sequence identity, more preferably at least about 96% amino acid sequence identity, more preferably at least about 97% amino acid sequence identity, more preferably at least about 98% amino acid sequence identity and
  • a PRO509 variant will have at least about 80% amino acid sequence identity, more preferably at least about 81% amino acid sequence identity, more preferably at least about 82% amino acid sequence identity, more preferably at least about 83% amino acid sequence identity, more preferably at least about 84% amino acid sequence identity, more preferably at least about 85% amino acid sequence identity, more preferably at least about 86% amino acid sequence identity, more preferably at least about 87% amino acid sequence identity, more preferably at least about 88% amino acid sequence identity, more preferably at least about 89% amino acid sequence identity, more preferably at least about 90% amino acid sequence identity, more preferably at least about 91% amino acid sequence identity, more preferably at least about 92% amino acid sequence identity, more preferably at least about 93% amino acid sequence identity, more preferably at least about 94% amino acid sequence identity, more preferably at least about 95% amino acid sequence identity, more preferably at least about 96% amino acid sequence identity, more preferably at least about 97% amino acid sequence identity, more preferably at least about 98% amino acid sequence identity and
  • a PRO866 variant will have at least about 80% amino acid sequence identity, more preferably at least about 81% amino acid sequence identity, more preferably at least about 82% amino acid sequence identity, more preferably at least about 83% amino acid sequence identity, more preferably at least about 84% amino acid sequence identity, more preferably at least about 85% amino acid sequence identity, more preferably at least about 86% amino acid sequence identity, more preferably at least about 87% amino acid sequence identity, more preferably at least about 88% amino acid sequence identity, more preferably at least about 89% amino acid sequence identity, more preferably at least about 90% amino acid sequence identity, more preferably at least about 91% amino acid sequence identity, more preferably at least about 92% amino acid sequence identity, more preferably at least about 93% amino acid sequence identity, more preferably at least about 94% amino acid sequence identity, more preferably at least about 95% amino acid sequence identity, more preferably at least about 96% amino acid sequence identity, more preferably at least about 97% amino acid sequence identity, more preferably at least about 98% amino acid sequence identity and yet
  • PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 and PRO866 variant polypeptides do not encompass the native PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 and PR0866 polypeptide sequence.
  • PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 and PR0866 variant polypeptides are at least about 10 amino acids in length, often at least about 20 amino acids in length, more often at least about 30 amino acids in length, more often at least about 40 amino acids in length, more often at least about 50 amino acids in length, more often at least about 60 amino acids in length, more often at least about 70 amino acids in length, more often at least about 80 amino acids in length, more often at least about 90 amino acids in length, more often at least about 100 amino acids in length, more often at least about 150 amino acids in length, more often at least about 200 amino acids in length, more often at least about 250 amino acids in length, more often at least about 300 amino acids in length, or more.
  • Table 1 provides the complete source code for the ALIGN-2 sequence comparison computer program. This source code may be routinely compiled for use on a UNIX operating system to provide the ALIGN-2 sequence comparison computer program.
  • Tables 2A-2D show hypothetical exemplifications for using the below described method to determine % amino acid sequence identity (Tables 2A-2B) and % nucleic acid sequence identity (Tables 2C-2D) using the ALIGN-2 sequence comparison computer program, wherein "PRO” represents the amino acid sequence of a hypothetical PRO 179, PRO207,PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide of interest, "Comparison Protein” represents the amino acid sequence of a polypeptide against which the "PRO” polypeptide of interest is being compared, "PRO-DNA” represents a hypothetical PROl 79-, PRO207-, PRO320-, PR0219-, PR0221-, PR0224-, PR0328-, PRO301-, PR0526-, PR0362-, PR0356-, PRO509- or PR0866-encoding nucleic acid sequence of interest, "Comparison DNA
  • filel and f ⁇ le2 are two dna or two protein sequences.
  • Max file length is 65535 (limited by unsigned short x in the jmp struct)
  • a sequence with 1/3 or more of its elements ACGTU is assumed to be DNA
  • the program may create a t p file in /tmp to hold info about traceback.
  • *ps[ ⁇ ] toupper(*ps[ ⁇ ]), po[ ⁇ ] + + , ps[ ⁇ ] + + ,
  • *py++ *px; else if ( ⁇ slower(*px))
  • *py++ toupper(*px); if ( ⁇ ndex("ATGCU",*(py-l))) natgc + + ;
  • Percent (%) amino acid sequence identity with respect to the PROl 79, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 and PR0866 polypeptide sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in a PR0179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity.
  • Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are obtained as described below by using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1.
  • the ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code shown in Table 1 has been filed with user documentation in the U.S.
  • the ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1.
  • the ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
  • % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows:
  • % amino acid sequence identity values used herein are obtained as described above using the ALIGN-2 sequence comparison computer program. However, % amino acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al, Nucleic Acids Res.. 25:3389-3402 (1997)). The NCBI-BLAST2 sequence comparison program may be downloaded from http://www.ncbi.nlm.nih.gov.
  • the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:
  • % amino acid sequence identity may also be determined using the WU-BLAST-2 computer program (Altschul et al, Methods in Enzvmology, 266:460-480 (1996)). Most of the WU-BLAST-2 search parameters are set to the default values. Those not set to default values, i.e.
  • a % amino acid sequence identity value is determined by dividing (a) the number of matching identical amino acids residues between the amino acid sequence of the PRO polypeptide of interest having a sequence derived from the native PRO polypeptide and the comparison amino acid sequence of interest (i.e., the sequence against which the PRO polypeptide of interest is being compared which may be a PRO variant polypeptide) as determined by WU-BLAST-2 by (b) the total number of amino acid residues of the PRO polypeptide of interest.
  • amino acid sequence A is the comparison amino acid sequence of interest and the amino acid sequence B is the amino acid sequence of the PRO polypeptide of interest.
  • PROl 79 variant polynucleotide or "PRO 179 variant nucleic acid sequence” means a nucleic acid molecule which encodes an active PRO 179 polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with either (a) a nucleic acid sequence which encodes residues 1 or about 17 to 460 of the PROl 79 polypeptide shown in Figure 2 (SEQ ID NO:2), (b) a nucleic acid sequence which encodes amino acids X to 460 of the PRO 179 polypeptide shown in Figure 2 (SEQ ID NO:2), wherein X is any amino acid residue from 12 to 21 of Figure 2 (SEQ ID NO:2), or (c) a nucleic acid sequence which encodes another specifically derived fragment of the amino acid sequence shown in Figure 2 (SEQ ID NO:2).
  • a PROl 79 variant polynucleotide will have at least about 80% nucleic acid sequence identity, more preferably at least about 81% nucleic acid sequence identity, more preferably at least about 82% nucleic acid sequence identity, more preferably at least about 83% nucleic acid sequence identity, more preferably at least about 84% nucleic acid sequence identity, more preferably at least about 85% nucleic acid sequence identity, more preferably at least about 86% nucleic acid sequence identity, more preferably at least about 87% nucleic acid sequence identity, more preferably at least about 88% nucleic acid sequence identity, more preferably at least about 89% nucleic acid sequence identity, more preferably at least about 90% nucleic acid sequence identity, more preferably at least about 91% nucleic acid sequence identity, more preferably at least about 92% nucleic acid sequence identity, more preferably at least about 93% nucleic acid sequence identity, more preferably at least about 94% nucleic acid sequence identity, more preferably at least about 95% nucleic acid sequence identity
  • PRO207 variant polynucleotide or "PRO207 variant nucleic acid sequence” means a nucleic acid molecule which encodes an active PRO207 polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with either (a) a nucleic acid sequence which encodes residues 1 or about 41 to 249 of the PRO207 polypeptide shown in Figure 4 (SEQ ID NO:7), (b) a nucleic acid sequence which encodes amino acids X to 249 of the PRO207 polypeptide shown in Figure 4 (SEQ ID NO:7), wherein X is any amino acid residue from 36 to 45 of Figure 4 (SEQ ID NO:7), or (c) a nucleic acid sequence which encodes another specifically derived fragment of the amino acid sequence shown in Figure 4 (SEQ ID NO:7).
  • a PRO207 variant polynucleotide will have at least about 80% nucleic acid sequence identity, more preferably at least about 81% nucleic acid sequence identity, more preferably at least about 82% nucleic acid sequence identity, more preferably at least about 83% nucleic acid sequence identity, more preferably at least about 84% nucleic acid sequence identity, more preferably at least about 85% nucleic acid sequence identity, more preferably at least about 86% nucleic acid sequence identity, more preferably at least about 87% nucleic acid sequence identity, more preferably at least about 88% nucleic acid sequence identity, more preferably at least about 89% nucleic acid sequence identity, more preferably at least about 90% nucleic acid sequence identity, more preferably at least about 91% nucleic acid sequence identity, more preferably at least about 92% nucleic acid sequence identity, more preferably at least about 93% nucleic acid sequence identity, more preferably at least about 94% nucleic acid sequence identity, more preferably at least about 95% nucleic acid sequence identity, more
  • PRO320 variant polynucleotide or "PRO320 variant nucleic acid sequence” means a nucleic acid molecule which encodes an active PRO320 polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with either (a) a nucleic acid sequence which encodes residues 1 or about 22 to 338 of the PRO320 polypeptide shown in Figure 6 (SEQ ID NO: 10), (b) a nucleic acid sequence which encodes amino acids X to 338 of the PRO320 polypeptide shown in Figure 6 (SEQ ID NO: 10), wherein X is any amino acid residue from 17 to 26 of Figure 6 (SEQ ID NO: 10), or (c) a nucleic acid sequence which encodes another specifically derived fragment of the amino acid sequence shown in Figure 6 (SEQ ID NO: 10).
  • a PRO320 variant polynucleotide will have at least about 80% nucleic acid sequence identity, more preferably at least about 81% nucleic acid sequence identity, more preferably at least about 82% nucleic acid sequence identity, more preferably at least about 83% nucleic acid sequence identity, more preferably at least about 84% nucleic acid sequence identity, more preferably at least about 85% nucleic acid sequence identity, more preferably at least about 86% nucleic acid sequence identity, more preferably at least about 87% nucleic acid sequence identity, more preferably at least about 88% nucleic acid sequence identity, more preferably at least about 89% nucleic acid sequence identity, more preferably at least about 90% nucleic acid sequence identity, more preferably at least about 91% nucleic acid sequence identity, more preferably at least about 92% nucleic acid sequence identity, more preferably at least about 93% nucleic acid sequence identity, more preferably at least about 94% nucleic acid sequence identity, more preferably at least about 95% nucleic acid sequence identity, more
  • PR0219 variant polynucleotide or "PR0219 variant nucleic acid sequence” means a nucleic acid molecule which encodes an active PR0219 polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with either (a) a nucleic acid sequence which encodes residues 1 or about 24 to 1005 of the PR0219 polypeptide shown in Figure 8 (SEQ ID NO: 15), (b) a nucleic acid sequence which encodes amino acids X to 1005 of the PR0219 polypeptide shown in Figure 8 (SEQ ID NO: 15), wherein X is any amino acid residue from 19 to 28 of Figure 8 (SEQ ID NO: 15), or (c) a nucleic acid sequence which encodes another specifically derived fragment of the amino acid sequence shown in Figure 8 (SEQ ID NO: 15).
  • a PR0219 variant polynucleotide will have at least about 80% nucleic acid sequence identity, more preferably at least about 81% nucleic acid sequence identity, more preferably at least about 82% nucleic acid sequence identity, more preferably at least about 83% nucleic acid sequence identity, more preferably at least about 84% nucleic acid sequence identity, more preferably at least about 85% nucleic acid sequence identity, more preferably at least about 86% nucleic acid sequence identity, more preferably at least about 87% nucleic acid sequence identity, more preferably at least about 88% nucleic acid sequence identity, more preferably at least about 89% nucleic acid sequence identity, more preferably at least about 90% nucleic acid sequence identity, more preferably at least about 91% nucleic acid sequence identity, more preferably at least about 92% nucleic acid sequence identity, more preferably at least about 93% nucleic acid sequence identity, more preferably at least about 94% nucleic acid sequence identity, more preferably at least about 95% nucleic acid sequence identity,
  • PR0221 variant polynucleotide or "PR0221 variant nucleic acid sequence” means a nucleic acid molecule which encodes an active PR0221 polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with either (a) a nucleic acid sequence which encodes residues 1 or about 34 to 259 of the PR0221 polypeptide shown in Figure 10 (SEQ ID NO:20), (b) a nucleic acid sequence which encodes amino acids X to 259 of the PR0221 polypeptide shown in Figure 10 (SEQ ID NO:20), wherein X is any amino acid residue from 29 to 38 of Figure 10 (SEQ ID NO:20), (c) 1 or about 34 to X of Figure 10 (SEQ ID NO:20), wherein X is any amino acid from amino acid 199 to amino acid 208 of Figure 10 (SEQ ID NO:20), or (d) a nucleic acid sequence which encodes another specifically derived fragment of the amino acid sequence shown in Figure 10 (SEQ ID NO:20
  • a PR0221 variant polynucleotide will have at least about 80% nucleic acid sequence identity, more preferably at least about 81 % nucleic acid sequence identity, more preferably at least about 82% nucleic acid sequence identity, more preferably at least about 83% nucleic acid sequence identity, more preferably at least about 84% nucleic acid sequence identity, more preferably at least about 85% nucleic acid sequence identity, more preferably at least about 86% nucleic acid sequence identity, more preferably at least about 87% nucleic acid sequence identity, more preferably at least about 88% nucleic acid sequence identity, more preferably at least about 89% nucleic acid sequence identity, more preferably at least about 90% nucleic acid sequence identity, more preferably at least about 91% nucleic acid sequence identity, more preferably at least about 92% nucleic acid sequence identity, more preferably at least about 93% nucleic acid sequence identity, more preferably at least about 94% nucleic acid sequence identity, more preferably at least about 95% nucleic acid sequence
  • PR0221 polynucleotide variants do not encompass the native PR0221 nucleotide sequence.
  • PR0224 variant polynucleotide or PR0224 variant nucleic acid sequence means a nucleic acid molecule which encodes an active PR0224 polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with either (a) a nucleic acid sequence which encodes residues 1 or about 31 to 282 of the PR0224 polypeptide shown in Figure 12 (SEQ ID N0:25), (b) a nucleic acid sequence which encodes amino acids X to 282 of the PR0224 polypeptide shown in Figure 12 (SEQ ID NO:25), wherein X is any amino acid residue from 26 to 35 of Figure 12 (SEQ ID NO:25), (c) 1 or about 31 to X of Figure 12 (SEQ ID NO:25), wherein X is any amino acid from amino acid 226 to amino acid 235 of Figure 12 (SEQ ID NO:25), or (d) a nucle
  • a PR0224 variant polynucleotide will have at least about 80% nucleic acid sequence identity, more preferably at least about 81% nucleic acid sequence identity, more preferably at least about 82% nucleic acid sequence identity, more preferably at least about 83% nucleic acid sequence identity, more preferably at least about 84% nucleic acid sequence identity, more preferably at least about 85% nucleic acid sequence identity, more preferably at least about 86% nucleic acid sequence identity, more preferably at least about 87% nucleic acid sequence identity, more preferably at least about 88% nucleic acid sequence identity, more preferably at least about 89% nucleic acid sequence identity, more preferably at least about 90% nucleic acid sequence identity, more preferably at least about 91% nucleic acid sequence identity, more preferably at least about 92% nucleic acid sequence identity, more preferably at least about 93% nucleic acid sequence identity, more preferably at least about 94% nucleic acid sequence identity, more preferably at least about 95% nucleic acid sequence identity,
  • PR0224 polynucleotide variants do not encompass the native PR0224 nucleotide sequence.
  • PR0328 variant polynucleotide or "PR0328 variant nucleic acid sequence” means a nucleic acid molecule which encodes an active PR0328 polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with either (a) a nucleic acid sequence which encodes residues 1 or about 23 to 463 of the PR0328 polypeptide shown in Figure 14 (SEQ ID NO:30), (b) a nucleic acid sequence which encodes amino acids X to 463 of the PR0328 polypeptide shown in Figure 14 (SEQ ID NO:30), wherein X is any amino acid residue from 18 to 27 of Figure 14 (SEQ ID NO:30), or (c) a nucleic acid sequence which encodes another specifically derived fragment of the amino acid sequence shown in Figure 14 (SEQ ID NO:30).
  • a PR0328 variant polynucleotide will have at least about 80% nucleic acid sequence identity, more preferably at least about 81% nucleic acid sequence identity, more preferably at least about 82% nucleic acid sequence identity, more preferably at least about 83% nucleic acid sequence identity, more preferably at least about 84% nucleic acid sequence identity, more preferably at least about 85% nucleic acid sequence identity, more preferably at least about 86% nucleic acid sequence identity, more preferably at least about 87% nucleic acid sequence identity, more preferably at least about 88% nucleic acid sequence identity, more preferably at least about 89% nucleic acid sequence identity, more preferably at least about 90% nucleic acid sequence identity, more preferably at least about 91 % nucleic acid sequence identity, more preferably at least about 92% nucleic acid sequence identity, more preferably at least about 93% nucleic acid sequence identity, more preferably at least about 94% nucleic acid sequence identity, more preferably at least about 95% nucleic acid sequence
  • PRO301 variant polynucleotide or "PRO301 variant nucleic acid sequence” means a nucleic acid molecule which encodes an active PRO301 polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with either (a) a nucleic acid sequence which encodes residues 1 or about 28 to 299 of the PRO301 polypeptide shown in Figure 16 (SEQ ID NO:35), (b) a nucleic acid sequence which encodes amino acids X to 299 of the PRO301 polypeptide shown in Figure 16 (SEQ ID NO:35), wherein X is any amino acid residue from 23 to 32 of Figure 16 (SEQ ID NO:35), (c) 1 or about 28 to X of Figure 16 (SEQ ID NO:35), wherein X is any amino acid from amino acid 230 to amino acid 239 of Figure 16 (SEQ ID NO:35), or (d) a nucleic acid sequence which encodes another specifically derived fragment of the amino acid sequence shown in Figure 16 (SEQ ID NO:35).
  • a PRO301 variant polynucleotide will have at least about 80% nucleic acid sequence identity, more preferably at least about 81% nucleic acid sequence identity, more preferably at least about 82% nucleic acid sequence identity, more preferably at least about 83% nucleic acid sequence identity, more preferably at least about 84% nucleic acid sequence identity, more preferably at least about 85% nucleic acid sequence identity, more preferably at least about 86% nucleic acid sequence identity, more preferably at least about 87% nucleic acid sequence identity, more preferably at least about 88% nucleic acid sequence identity, more preferably at least about 89% nucleic acid sequence identity, more preferably at least about 90% nucleic acid sequence identity, more preferably at least about 91% nucleic acid sequence identity, more preferably at least about 92% nucleic acid sequence identity, more preferably at least about 93% nucleic acid sequence identity, more preferably at least about 94% nucleic acid sequence identity, more preferably at least about 95% nucleic acid sequence identity, more
  • PR0526 variant polynucleotide or "PR0526 variant nucleic acid sequence” means a nucleic acid molecule which encodes an active PR0526 polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with either (a) a nucleic acid sequence which encodes residues 1 or about 27 to 473 of the PR0526 polypeptide shown in Figure 18 (SEQ ID NO:43), (b) a nucleic acid sequence which encodes amino acids X to 473 of the PR0526 polypeptide shown in Figure 18 (SEQ ID NO:43), wherein X is any amino acid residue from 22 to 31 of Figure 18 (SEQ ID NO:43), or (c) a nucleic acid sequence which encodes another specifically derived fragment of the amino acid sequence shown in Figure 18 (SEQ ID NO:43).
  • a PR0526 variant polynucleotide will have at least about 80% nucleic acid sequence identity, more preferably at least about 81% nucleic acid sequence identity, more preferably at least about 82% nucleic acid sequence identity, more preferably at least about 83% nucleic acid sequence identity, more preferably at least about 84% nucleic acid sequence identity, more preferably at least about 85% nucleic acid sequence identity, more preferably at least about 86% nucleic acid sequence identity, more preferably at least about 87% nucleic acid sequence identity, more preferably at least about 88% nucleic acid sequence identity, more preferably at least about 89% nucleic acid sequence identity, more preferably at least about 90% nucleic acid sequence identity, more preferably at least about 91% nucleic acid sequence identity, more preferably at least about 92% nucleic acid sequence identity, more preferably at least about 93% nucleic acid sequence identity, more preferably at least about 94% nucleic acid sequence identity, more preferably at least about 95% nucleic acid sequence identity,
  • PR0526 polynucleotide variants do not encompass the native PR0526 nucleotide sequence.
  • PR0362 variant polynucleotide or "PR0362 variant nucleic acid sequence” means a nucleic acid molecule which encodes an active PR0362 polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with either (a) a nucleic acid sequence which encodes residues 1 or about 20 to 321 of the PR0362 polypeptide shown in Figure 20 (SEQ ID NO:48), (b) a nucleic acid sequence which encodes amino acids X to 321 of the PR0362 polypeptide shown in Figure 20 (SEQ ID NO:48), wherein X is any amino acid residue from 15 to 24 of Figure 20 (SEQ ID NO:48), (c) 1 or about 20 to X of Figure 20 (SEQ ID NO:48), wherein X is any amino acid from amino acid 276 to amino acid 285 of Figure 20 (SEQ ID NO:48), or (d) a nu
  • a PR0362 variant polynucleotide will have at least about 80% nucleic acid sequence identity, more preferably at least about 81 % nucleic acid sequence identity, more preferably at least about 82% nucleic acid sequence identity, more preferably at least about 83% nucleic acid sequence identity, more preferably at least about 84% nucleic acid sequence identity, more preferably at least about 85% nucleic acid sequence identity, more preferably at least about 86% nucleic acid sequence identity, more preferably at least about 87% nucleic acid sequence identity, more preferably at least about 88% nucleic acid sequence identity, more preferably at least about 89% nucleic acid sequence identity, more preferably at least about 90% nucleic acid sequence identity, more preferably at least about 91% nucleic acid sequence identity, more preferably at least about 92% nucleic acid sequence identity, more preferably at least about 93% nucleic acid sequence identity, more preferably at least about 94% nucleic acid sequence identity, more preferably at least about 95% nucleic acid sequence
  • PR0356 variant polynucleotide or "PR0356 variant nucleic acid sequence” means a nucleic acid molecule which encodes an active PR0356 polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with either (a) a nucleic acid sequence which encodes residues 1 or about 27 to 346 of the PR0356 polypeptide shown in Figure 22 (SEQ ID NO:55), (b) a nucleic acid sequence which encodes amino acids X to 346 of the PR0356 polypeptide shown in Figure 22 (SEQ ID NO:55), wherein X is any amino acid residue from 22 to 31 of Figure 22 (SEQ ID NO:55), or (c) a nucleic acid sequence which encodes another specifically derived fragment of the amino acid sequence shown in Figure 22 (SEQ ID NO:55).
  • a PR0356 variant polynucleotide will have at least about 80% nucleic acid sequence identity, more preferably at least about 81% nucleic acid sequence identity, more preferably at least about 82% nucleic acid sequence identity, more preferably at least about 83% nucleic acid sequence identity, more preferably at least about 84% nucleic acid sequence identity, more preferably at least about 85% nucleic acid sequence identity, more preferably at least about 86% nucleic acid sequence identity, more preferably at least about 87% nucleic acid sequence identity, more preferably at least about 88% nucleic acid sequence identity, more preferably at least about 89% nucleic acid sequence identity, more preferably at least about 90% nucleic acid sequence identity, more preferably at least about 91% nucleic acid sequence identity, more preferably at least about 92% nucleic acid sequence identity, more preferably at least about 93% nucleic acid sequence identity, more preferably at least about 94% nucleic acid sequence identity, more preferably at least about 95% nucleic acid sequence identity,
  • PRO509 variant polynucleotide or "PRO509 variant nucleic acid sequence” means a nucleic acid molecule which encodes an active PRO509 polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with either (a) a nucleic acid sequence which encodes residues 1 or about 37 to 283 of the PRO509 polypeptide shown in Figure 24 (SEQ ID NO:60), (b) a nucleic acid sequence which encodes amino acids X to 283 of the PRO509 polypeptide shown in Figure 24 (SEQ ID NO:60), wherein X is any amino acid residue from 32 to 41 of Figure 24 (SEQ ID NO:60), (c) 1 or about 37 to X of Figure 24 (SEQ ID NO:60), wherein X is any amino acid from amino acid 200 to amino acid 209 of Figure 24 (SEQ ID NO:60), or (d) a nucleic acid sequence which encodes another specifically derived fragment of the amino acid sequence shown in Figure 24 (SEQ ID NO:60).
  • a PRO509 variant polynucleotide will have at least about 80% nucleic acid sequence identity, more preferably at least about 81% nucleic acid sequence identity, more preferably at least about 82% nucleic acid sequence identity, more preferably at least about 83% nucleic acid sequence identity, more preferably at least about 84% nucleic acid sequence identity, more preferably at least about 85% nucleic acid sequence identity, more preferably at least about 86% nucleic acid sequence identity, more preferably at least about 87% nucleic acid sequence identity, more preferably at least about 88% nucleic acid sequence identity, more preferably at least about 89% nucleic acid sequence identity, more preferably at least about 90% nucleic acid sequence identity, more preferably at least about 91% nucleic acid sequence identity, more preferably at least about 92% nucleic acid sequence identity, more preferably at least about 93% nucleic acid sequence identity, more preferably at least about 94% nucleic acid sequence identity, more preferably at least about 95% nucleic acid sequence identity,
  • PR0866 variant polynucleotide or "PR0866 variant nucleic acid sequence” means a nucleic acid molecule which encodes an active PRO866 polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with either (a) a nucleic acid sequence which encodes residues 1 or about 27 to 331 of the PR0866 polypeptide shown in Figure 26 (SEQ ID NO:62), (b) a nucleic acid sequence which encodes amino acids X to 331 of the PR0866 polypeptide shown in Figure 26 (SEQ ID NO:62), wherein X is any amino acid residue from 22 to 31 of Figure 26 (SEQ ID NO:62), or (c) a nucleic acid sequence which encodes another specifically derived fragment of the amino acid sequence shown in Figure 26 (SEQ ID NO:62).
  • a PR0866 variant polynucleotide will have at least about 80% nucleic acid sequence identity, more preferably at least about 81% nucleic acid sequence identity, more preferably at least about 82% nucleic acid sequence identity, more preferably at least about 83% nucleic acid sequence identity, more preferably at least about 84% nucleic acid sequence identity, more preferably at least about 85% nucleic acid sequence identity, more preferably at least about 86% nucleic acid sequence identity, more preferably at least about 87% nucleic acid sequence identity, more preferably at least about 88% nucleic acid sequence identity, more preferably at least about 89% nucleic acid sequence identity, more preferably at least about 90% nucleic acid sequence identity, more preferably at least about 91% nucleic acid sequence identity, more preferably at least about 92% nucleic acid sequence identity, more preferably at least about 93% nucleic acid sequence identity, more preferably at least about 94% nucleic acid sequence identity, more preferably at least about 95% nucleic acid sequence identity,
  • PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 and PR0866 variant polynucleotides are at least about 30 nucleotides in length, often at least about 60 nucleotides in length, more often at least about 90 nucleotides in length, more often at least about 120 nucleotides in length, more often at least about 150 nucleotides in length, more often at least about 180 nucleotides in length, more often at least about 210 nucleotides in length, more often at least about 240 nucleotides in length, more often at least about 270 nucleotides in length, more often at least about 300 nucleotides in length, more often at least about 450 nucleotides in length, more often at least about 600 nucleotides in length, more often at least about 900 nucleotides in length, or more.
  • Percent (%) nucleic acid sequence identity with respect to the PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 and PR0866 polypeptide-encoding nucleic acid sequences identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in a PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide-encoding nucleic acid sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity.
  • Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared. For purposes herein, however, % nucleic acid sequence identity values are obtained as described below by using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1.
  • the ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code shown in Table 1 has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087.
  • the ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided inTable 1.
  • the ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
  • % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D is calculated as follows:
  • % nucleic acid sequence identity values used herein are obtained as described above using the ALIGN-2 sequence comparison computer program. However, % nucleic acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al, Nucleic Acids Res.. _25:3389-3402 (1997)). The NCBI-BLAST2 sequence comparison program may be downloaded from http://www.ncbi.nlm.nih.gov.
  • % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D is calculated as follows:
  • a % nucleic acid sequence identity value is determined by dividing (a) the number of matching identical nucleotides between the nucleic acid sequence of the PRO polypeptide- encoding nucleic acid molecule of interest having a sequence derived from the native sequence PRO polypeptide- encoding nucleic acid and the comparison nucleic acid molecule of interest (i.e., the sequence against which the PRO polypeptide-encoding nucleic acid molecule of interest is being compared which may be a variant PRO polynucleotide) as determined by WU-BLAST-2 by (b) the total number of nucleotides of the PRO polypeptide- encoding nucleic acid molecule of interest.
  • nucleic acid sequence A is the comparison nucleic acid molecule of interest and the nucleic acid sequence B is the nucleic acid sequence of the PRO polypeptide-encoding nucleic acid molecule of interest.
  • PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 and PRO866 variant polynucleotides are nucleic acid molecules that encode an active PR0179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide, respectively, and which are capable of hybridizing, preferably under stringent hybridization and wash conditions, to nucleotide sequences encoding the full-length PRO 179 polypeptide shown in Figure 2 (SEQ ID NO:2), to nucleotide sequences encoding the full-length PRO207 polypeptide shown in Figure 4 (SEQ ID NO:7), to nucleotide sequences encoding the full-length PRO320 polypeptide shown in Figure 6 (SEQ ID NO: 10), to nucleotide sequences encoding the full
  • PROl 79, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 and PRO866 variant polypeptides may be those that are encoded by a PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 variant polynucleotide.
  • amino acid residues in the sequences compared that are not only identical, but also those that have similar properties are those that are either identical to the amino acid residue of interest or are a preferred substitution (as defined in Table 3 below) of the amino acid residue of interest.
  • the % value of positives of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows:
  • isolated when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Preferably, the isolated polypeptide is free of association with all components with which it is naturally associated. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes.
  • the polypeptide will be purified ( 1 ) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain.
  • Isolated polypeptide includes polypeptide in situ within recombinant cells, since at least one component of the PROl 79, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.
  • An "isolated" nucleic acid molecule encoding a PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide or an "isolated" nucleic acid molecule encoding an anti-PRO 179, anti-PRO207, anti-PRO320, anti-PR0219, anti-PR0221 , anti-PR0224, anti- PR0328, anti-PRO301 , anti-PR0526,anti-PR0362, anti-PR0356, anti-PRO509 or anti-PR0866 antibody is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the PROl 79-, PRO207-, PRO320-, PR0219-, PR0221-, PR0224-, PR0328-, PRO301-, PR0526-, PR0362-, PR
  • the isolated nucleic acid is free of association with all components with which it is naturally associated.
  • Isolated nucleic acid molecules therefore are distinguished from the PRO 179-, PRO207-, PRO320-, PR0219-, PR0221 -, PR0224-, PRO328-,PRO301 -,PR0526-,PR0362-, PR0356-, PRO509- or PR0866-encoding nucleic acid molecule or from the anti-PR0179-, anti-PRO207-, anti- PRO320-, anti-PR0219-, anti-PR0221 -, anti-PR0224-, anti-PR0328-, anti-PRO301-, anti-PR0526-,anti- PR0362-, anti-PR0356-, anti-PRO509-or anti-PR0866-encoding nucleic acid molecule as it exists in natural cells.
  • control sequences refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism.
  • the control sequences that are suitable for prokaryotes include a promoter, optionally an operator sequence, and a ribosome binding site.
  • Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
  • Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence.
  • DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide;
  • a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or
  • a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
  • "operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
  • antibody is used in the broadest sense and specifically covers, for example, single anti- PROl 79, anti-PRO207, anti-PRO320, anti-PR0219, anti-PR0221 ,anti-PRO224,anti-PRO328,anti-PRO301 ,anti- PR0526,anti- PR0362, anti-PR0356, anti-PRO509 and anti-PR0866 monoclonal antibodies (including agonist antibodies), anti-PROl 79, anti-PRO207, anti-PRO320, anti-PR0219, anti-PR0221 , anti-PR0224, anti-PR0328, anti-PRO301 , anti-PR0526,anti-PR0362, anti-PR0356, anti-PRO509 and anti-PR0866 antibody compositions with polyepitopic specificity, single chain anti-PRO 179, anti-PRO207, anti-PRO320, anti-PR0219, anti-PR0221 , anti-PR0224, anti-PR0328, anti-PRO301 , anti-PR0526,anti-PR03
  • the term "monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts. "Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used.
  • “Stringent conditions” or “high stringency conditions”, as defined herein, may be identified by those that: (1 ) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50 °C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42 °C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 ⁇ g/ml), 0.1% SDS, and 10% dex
  • Modely stringent conditions may be identified as described by Sambrook et al. Molecular Cloning: A Laboratory Manual. New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and % SDS) less stringent that those described above.
  • An example of moderately stringent conditions is overnight incubation at 37 °C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C.
  • the skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.
  • the term "epitope tagged" when used herein refers to a chimeric polypeptide comprising a PRO 179,
  • tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused.
  • the tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes. Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues).
  • immunoadhesin designates antibody-like molecules which combine the binding specificity of a heterologous protein (an “adhesin”) with the effector functions of immunoglobulin constant domains.
  • the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is “heterologous"), and an immunoglobulin constant domain sequence.
  • the adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand.
  • the immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG- 1 , IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD or IgM.
  • immunoglobulin such as IgG- 1 , IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD or IgM.
  • “Active” or “activity” for the purposes herein refers to form(s) of PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 which retain a biological and/or an immunological activity of native or naturally-occurring PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866, wherein "biological” activity refers to a biological function (either inhibitory or stimulatory) caused by a native or naturally-occurring PROl 79, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 other than the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occ
  • Bio activity in the context of an antibody or another agonist that can be identified by the screening assays disclosed herein (e.g., an organic or inorganic small molecule, peptide, etc.) is used to refer to the ability of such molecules to invoke one or more of the effects listed herein in connection with the definition of a "therapeutically effective amount.”
  • biological activity is the ability to inhibitneoplastic cell growth or proliferation.
  • a preferred biological activity is inhibition, including slowing or complete stopping, of the growth of a target tumor (e.g., cancer) cell.
  • Another preferred biological activity is cytotoxic activity resulting in the death of the target tumor (e.g. , cancer) cell.
  • Yet another preferred biological activity is the induction of apoptosis of a target tumor (e.g., cancer) cell.
  • immunological cross-reactivity means immunological cross-reactivity with at least one epitope of a PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide.
  • “Immunological cross-reactivity” as used herein means that the candidate polypeptide is capable of competitively inhibiting the qualitative biological activity of a PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide having this activity with polyclonal antisera raised against the known active PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide.
  • Such antisera are prepared in conventional fashion by injecting goats or rabbits, for example, subcutaneously with the known active analogue in complete Freund's adjuvant, followed by booster intraperitoneal or subcutaneousinjectionin incomplete Freunds.
  • the immunological cross-reactivity preferably is "specific", which means that the binding affinity of the immunologically cross-reactive molecule (e.g., antibody) identified, to the corresponding PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide is significantly higher (preferably at least about 2-times, more preferably at least about 4-times, even more preferably at least about 6-times, most preferably at least about 8-times higher) than the binding affinity of that molecule to any other known native polypeptide.
  • Tuor refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous
  • cancer refers to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
  • cancer include but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More particular examples of such cancers include breast cancer, prostate cancer, colon cancer, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, liver cancer, bladder cancer, hepatoma, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer.
  • Treatment is an intervention performed with the intention of preventing the development or altering the pathology of a disorder. Accordingly, “treatment” refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented.
  • a therapeutic agent may directly decrease the pathology of tumor cells, or render the tumor cells more susceptible to treatment by other therapeutic agents, e.g., radiation and/or chemotherapy.
  • the "pathology" of cancer includes all phenomena that compromise the well-being of the patient. This includes, without limitation, abnormal or uncontrollable cell growth, metastasis, interference with the normal functioning of neighboring cells, release of cytokines or other secretory products at abnormal levels, suppression or aggravation of inflammatory or immunological response, etc.
  • an "effective amount” of a polypeptide disclosed herein or an agonist thereof, in reference to inhibition of neoplastic cell growth is an amount capable of inhibiting, to some extent, the growth of target cells.
  • the term includes an amount capable of invoking a growth inhibitory, cytostatic and/or cytotoxic effect and/or apoptosis of the target cells.
  • An "effective amount” of a PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide or an agonist thereof for purposes of inhibiting neoplastic cell growth may be determined empirically and in a routine manner.
  • a “therapeutically effective amount”, in reference to the treatment of tumor, refers to an amount capable of invoking one or more of the following effects: (1) inhibition, to some extent, of tumor growth, including, slowing down and complete growth arrest; (2) reduction in the number of tumor cells; (3) reduction in tumor size;
  • a "therapeutically effective amount" of a PROl 79, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide or an agonist thereof for purposes of treatment of tumor may be determined empirically and in a routine manner.
  • a “growth inhibitory amount” of a PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 orPR0866 polypeptide or an agonist thereof is an amount capable of inhibiting the growth of a cell, especially tumor, e.g., cancer cell, either in vitro or in vivo.
  • a "growth inhibitory amount" of a PR0179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide or an agonist thereof for purposes of inhibiting neoplastic cell growth may be determined empirically and in a routine manner
  • a "cytotoxic amount” of a PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide or an agonist thereof is an amount capable of causing the destruction of a cell, especially tumor, e g , cancer cell, either in vitro or in vivo
  • a "cytotoxic amount” 0fa PRO179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide or an agonist thereof for purposes of inhibiting neoplastic cell growth may be determined empirically and in a routine manner
  • cytotoxic agent refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells
  • the term is intended to include radioactive isotopes (e g , I 131 , 1 125 , Y 90 and Re 186 ), chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, fungal, plant or animal origin, or fragments thereof
  • chemotherapeutic agent is a chemical compound useful in the treatment of tumor, e g , cancer
  • chemotherapeutic agents include ad ⁇ amycin, doxorubicin, epirubicin, 5-fluorourac ⁇ l, cytosme arabinoside ("Ara-C"), cyclophosphamide, thiotepa, busulfan, cytoxm, taxoids, e g , pachtaxel (Taxol, B ⁇ stol- Myers Squibb Oncology, Princeton, NJ), and doxetaxel (Taxotere, Rh ⁇ ne-Poulenc Rorer, Antony, Rnace),toxotere, methotrexate, cisplatin, melphalan, vinblastine, bleomycin, etoposide, lfosfamide, mitomycin C, mitoxantrone, vmcnstine, vmorelbine, carbop
  • a “growth inhibitory agent” when used herein refers to a compound or composition which inhibits growth of a cell, especially tumor, e g , cancer cell, either in vitro or in vivo
  • the growth inhibitory agent is one which significantly reduces the percentage of the target cells in S phase
  • growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G 1 arrest and M- phase arrest
  • Classical M-phase blockers include the vincas (vmcnstine and vinblastine), taxol, and topo II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin
  • Those agents that arrest GI also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorourac ⁇ l, and ara-
  • cytokine is a generic term for proteins released by one cell population which act on another cell as intercellular mediators
  • lymphokines include lymphokines, monokines, and traditional polypeptide hormones Included among the cytokines are growth hormone such as human growth hormone, N- methionyl human growth hormone, and bovine growth hormone, parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxm, glycoprotem hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteiniz g hormone (LH), hepatic growth factor, fibroblast growth factor, prolactin, placental lactogen, tumor necrosis factor- and - ⁇ , mulle ⁇ an-inhibitmg substance; mouse gonadotropin- associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors such as NGF- ⁇ ; platelet-
  • growth hormone
  • cytokine includes proteins from natural sources or from recombinant cell culture and biologically active equivalents of the native sequence cytokines.
  • prodrug refers to a precursor or derivative form of a pharmaceutically active substance that is less cytotoxic to tumor cells compared to the parent drug and is capable of being enzymatically activated or converted into the more active parent form. See, e.g., Wilman, "Prodrugs in Cancer Chemotherapy", Biochemical Society Transactions, 14, pp. 375-382, 615th Meeting Harbor (1986) and Stella et al, “Prodrugs: A Chemical Approach to Targeted Drug Delivery,” Directed Drug Delivery.
  • the prodrugs of this invention include, but are not limited to, phosphate-containing prodrugs, thiophosphate-containing prodrugs, glycosylated prodrugs or optionally substituted phenylacetamide-containing prodrugs, 5-fluorocytosine and other 5-fluorouridine prodrugs which can be derivatized into a prodrug form for use in this invention include, but are not limited to, those chemotherapeutic agents described above.
  • agonist is used in the broadest sense and includes any molecule that mimics a biological activity of a native PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide disclosed herein.
  • Suitable agonist molecules specifically include agonist antibodies or antibody fragments, fragments or amino acid sequence variants of native PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptides, peptides, small organic molecules, etc.
  • Methods for identifying agonists of a PROl 79, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide may comprise contacting a tumor cell with a candidate agonist molecule and measuring the inhibition of tumor cell growth.
  • Chronic administration refers to administration of the agent(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time.
  • Intermittent administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature.
  • “Mammal” for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc. Preferably, the mammal is human.
  • Administration "in combination with" one or more further therapeutic agents includes simultaneous
  • Carriers as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution.
  • physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEENTM, polyethylene glycol (PEG), and PLURONICSTM.
  • buffers such as phosphate, citrate, and other organic acids
  • antioxidants including ascorbic acid
  • low molecular weight (less than about 10 residues) polypeptides proteins, such as serum album
  • Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies among the heavy chains of different immunoglobulin isotypes.
  • Each heavy and light chain also has regularly spaced intrachain disulfide bridges.
  • Each heavy chain has at one end a variable domain (V H ) followed by a number of constant domains.
  • Each light chain has a variable domain at one end (V L ) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light-chain variable domain is aligned with the variable domain of the heavy chain.
  • Particular amino acid residues are believed to form an interface between the light- and heavy-chain variable domains.
  • variable refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions both in the light-chain and the heavy-chain variable domains. The more highly conserved portions of variable domains are called the framework regions (FR).
  • CDRs complementarity-determining regions
  • FR framework regions
  • the variable domains of native heavy and light chains each comprise four FR regions, largely adopting a ⁇ -sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the ⁇ -sheet structure.
  • the CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies (see, Kabat et al, NIH Publ. No.91-3242, Vol. I, pages 647-669 (1991)).
  • the constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.
  • hypervariable region when used herein refers to the amino acid residues of an antibody which are responsible for antigen-binding.
  • the hypervariable region comprises amino acid residues from a "complementarity determining region" or "CDR" (i.e., residues 24-34 (LI), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and 31-35 (HI), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain; Kabat et al, Sequences of Proteins of Immunological Interest. 5th Ed. Public Health Service, National Institute of Health, Bethesda, MD. [ 1991 ]) and/or those residues from a "hypervariable loop" (/ ' . e.
  • Antibody fragments comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody.
  • antibody fragments include Fab, Fab', F(ab') 2 , and Fv fragments; diabodies; linear antibodies (Zapata et al, Protein Eng., 8(10): 1057-1062 [1995]); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
  • Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, each with a single antigen-binding site, and a residual "Fc” fragment, a designation reflecting the ability to crystallize readily.
  • Pepsin treatment yields an F(ab'), fragment that has two antigen-combining sites and is still capable of cross-linking antigen.
  • Fv is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the V H -V L dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
  • the Fab fragment also contains the constant domain of the light chain and the first constant domain (CH 1 ) of the heavy chain.
  • Fab fragments differ from Fab' fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH 1 domain including one or more cysteines from the antibody hinge region.
  • Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group.
  • F(ab') antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
  • immunoglobulins The "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains. Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g. , IgG 1 , IgG2, IgG3, IgG4, IgA, and IgA2.
  • immunoglobulins There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g. , IgG 1 , IgG2, I
  • the term "monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, . e. , the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparationswhich typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, unconta inated by other immunoglobulins.
  • the modifier "monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
  • the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al , Nature.256:495 [ 1975], or may be made by recombinant DNA methods (see, e.g. , U.S. Patent No.4,816,567).
  • the “monoclonal antibodies” may also be isolated from phage antibody libraries using the techniques described in Clackson et al, Nature, 352:624-628 [1991] and Marks et al, J. Mol. Biol., 222:581-597 (1991), for example.
  • the monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; Morrison et al, Proc. Natl. Acad. Sci. USA. 81:6851- 6855 [1984]).
  • chimeric antibodies immunoglobulins in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences
  • Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab') 2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin.
  • humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a CDR of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity, and capacity.
  • donor antibody such as mouse, rat or rabbit having the desired specificity, affinity, and capacity.
  • Fv FR residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • humanized antibodies may comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and maximize antibody performance.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence.
  • the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Fc immunoglobulin constant region
  • the humanized antibody includes a PRIMATIZEDTMantibody wherein the antigen-binding region of the antibody is derived from an antibody produced by immunizing macaque monkeys with the antigen of interest.
  • "Single-chain Fv" or "sFv” antibody fragments comprise the V H and V L domains of antibody, wherein these domains are present in a single polypeptide chain.
  • the Fv polypeptide further comprises a polypeptide linker between the V H and V L domains which enables the sFv to form the desired structure for antigen binding.
  • diabodies refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (V H ) connected to a light-chain variable domain (V L ) in the same polypeptide chain (V H - V L ).
  • V H heavy-chain variable domain
  • V L light-chain variable domain
  • the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites.
  • Diabodies are described more fully in, for example, EP 404,097; WO 93/1 1 161 ; and Hollinger et al, Proc. Natl. Acad. Sci. USA. 90:6444-6448 (1993).
  • an “isolated” antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes.
  • the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain.
  • Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.
  • label when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody.
  • the label may be detectable by itself (e.g., radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.
  • the label may also be a non-detectable entity such as a toxin.
  • solid phase is meant a non-aqueous matrix to which the antibody of the present invention can adhere.
  • solid phases encompassed herein include those formed partially or entirely of glass (e.g., controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones.
  • the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g., an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275, 149.
  • a “liposome” is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug (such as a PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide or antibody thereto) to a mammal.
  • a drug such as a PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide or antibody thereto
  • the components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.
  • a "small molecule” is defined herein to have a molecular weight below about 500 Daltons.
  • PRO17 A. Full-length PRO 179. PRO207. PRO320. PRQ219. PRQ221. PRQ224. PRQ328. PRO301. PRQ526. PRQ362. PRQ356. PRO509 and PRQ866 Polypeptides
  • the present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328,
  • PRO301 PRO305 , PR0526, PR0362, PR0356, PRO509 and PRO866.
  • cDNAs encoding PROl 79, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 and PR0866 polypeptides have been identified and isolated, as disclosed in further detail in the Examples below.
  • cDNA clones encoding PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, and PR0866 polypeptides have been deposited with the ATCC [with the exception of clone PRO509 which was not deposited with ATCC].
  • the actual nucleotide sequences of the clones can readily be determined by the skilled artisan by sequencing of the deposited clones using routine methods in the art.
  • the predicted amino acid sequences can be determined from the nucleotide sequences using routine skill.
  • PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 and PR0866 polypeptides described herein it is contemplated that PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 and PR0866 variants can be prepared.
  • PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 and PR0866 variants can be prepared by introducing appropriate nucleotide changes into the PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 DNA, and/or by synthesis of the desiredPRO 179, PRO207,PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide.
  • amino acid changes may alter post- translational processes of the PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide, such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics.
  • Variations may be a substitution, deletion or insertion of one or more codons encoding the PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 that results in a change in the amino acid sequence of the PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 as compared with the native sequence PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866.
  • the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of the PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866.
  • Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the desired activity may be found by comparing the sequence of the PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 with that of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology.
  • Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine, i.e., conservative amino acid replacements.
  • Insertions or deletions may optionally be in the range of about 1 to 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence.
  • PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 and PR0866 polypeptide fragments are provided herein. Such fragments may be truncated at the N-terminus or C-terminus, or may lack internal residues, for example, when compared with a full length native protein. Certain fragments lack amino acid residues that are not essential for a desired biological activity of the PR0179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide.
  • PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 and PR0866 fragments may be prepared by any of a number of conventional techniques. Desired peptide fragments may be chemically synthesized.
  • An alternative approach involves generating PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 and PR0866 fragments by enzymatic digestion, e.g., by treating the protein with an enzyme known to cleave proteins at sites defined by particular amino acid residues, or by digesting the DNA with suitable restriction enzymes and isolating the desired fragment.
  • Yet another suitable technique involves isolating and amplifying a DNA fragment encoding a desired polypeptide fragment, by polymerase chain reaction (PCR). Oligonucleotides that define the desired termini of the DNA fragment are employed at the 5' and 3' primers in the PCR.
  • PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 and PR0866 polypeptide fragments share at least one biological and/or immunological activity with the native PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptides shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:7), Figure 6 (SEQ ID NO: 10), Figure 8 (SEQ ID NO: 15), Figure 10 (SEQ ID NO:20), Figure 12 (SEQ ID NO:25), Figure 14 (SEQ ID NO:30), Figure 16 (SEQ ID NO:35), Figure 18 (SEQ ID NO:43), Figure 20 (SEQ ID NO:48), Figure 22 (SEQ ID NO:55), Figure 24 (SEQ ID NO:60), or Figure 26 (SEQ ID NO:62
  • Substantial modifications in function or immunological identity of the PROl 79, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
  • Naturally occurring residues are divided into groups based on common side-chain properties:
  • hydrophobic norleucine, met, ala, val, leu, ile
  • Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the remaining (non-conserved) sites.
  • the variations can be made using methods known in the art such as oligonucleotide-mediated (site- directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis [Carter et al., Nucl. Acids Res.. 13:4331 (1986); Zoller et al, Nucl. Acids Res..
  • Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence.
  • preferred scanning amino acids are relatively small, neutral amino acids.
  • amino acids include alanine, glycine, serine, and cysteine.
  • Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main- chain conformation of the variant [Cunningham and Wells, Science, 244: 1081-1085 (1989)].
  • Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions [Creighton, The Proteins. (W.H. Freeman & Co., N.Y.); Chothia, J. Mol. Biol.. 150: 1 (1976)]. If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used.
  • PRQ179 Modifications of PRQ179. PRO207. PRO320. PRQ219. PRQ221. PRQ224. PRQ328. PRO301. PRQ526, PRQ362, PRQ356. PRO509 and PRQ866
  • Covalent modifications of PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 and PRO866 are included within the scope of this invention.
  • One type of covalent modification includes reacting targeted amino acid residues of a PR0179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal residues of the PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866.
  • Derivatization with bifunctional agents is useful, for instance, for crosslinking PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 to a water-insoluble support matrix or surface for use in the method for purifying anti-PRO 179, anti- PRO207,anti-PRO320, anti-PR0219, anti-PR0221 , anti-PR0224, anti-PRO328,anti-PRO301 ,anti-PR0526,anti- PR0362, anti-PR0356, anti-PRO509 or anti-PR0866 antibodies, and vice-versa.
  • crosslinking agents include, e.g., l,l-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-l,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimidate.
  • Another type of covalent modification of the PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide.
  • “Altering the native glycosylation pattern” is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means), and/or adding one or more glycosylation sites that are not present in the native sequence PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866.
  • the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present.
  • Addition of glycosylation sites to the PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide may be accomplished by altering the amino acid sequence. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 (for O-linked glycosylation sites).
  • PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.
  • Another means of increasing the number of carbohydrate moieties on the PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp.259-306 (1981).
  • PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation.
  • Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophvs.. 259:52 (1987) and by Edge et al, Anal. Biochem.. 118:131 (1981).
  • Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al, Meth. Enzvmol., 138:350 (1987).
  • PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 comprises linking the PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301 ,144; 4,670,417; 4,791 ,192 or 4, 179,337.
  • PEG polyethylene glycol
  • PROl 79, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide of the present invention may also be modified in a way to form a chimeric molecule comprising PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 ,
  • PR0526, PR0362, PR0356, PRO509 or PR0866 fused to another, heterologous polypeptide or amino acid sequence.
  • such a chimeric molecule comprises a fusion of the PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind.
  • the epitope tag is generally placed at the amino- or carboxyl- terminus of the PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide.
  • epitope-tagged forms of the PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide can be detected using an antibody against the tag polypeptide.
  • provision of the epitope tag enables the PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag.
  • tag polypeptides and their respective antibodies are well known in the art.
  • poly-histidine poly-His
  • poly-histidine-glycine poly-His-gly
  • flu HA tag polypeptide and its antibody 12C A5 [Field et al, Mol. Cell. Biol., 8:2159-2165 (1988)]
  • c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E 10 antibodies thereto [Evan et al, Molecular and Cellular Biology, 5:3610-3616 (1985)]
  • Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al, Protein Engineering, 3(6):547-553 (1990)].
  • tag polypeptides include the Flag-peptide [Hopp eta , BioTechnology.6: 1204- 1210 (1988)]; the KT3 epitope peptide [Martin et al, Science, 255: 192-194 (1992)]; an ⁇ -tubulin epitope peptide [Skinner et al, J. Biol. Chem.. 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et l, Proc. Natl. Acad. Sci. USA. 87:6393-6397 (1990)].
  • the chimeric molecule may comprise a fusion of the PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide with an immunoglobulin or a particular region of an immunoglobulin.
  • an immunoglobulin or a particular region of an immunoglobulin.
  • a bivalent form of the chimeric molecule also referred to as an "immunoadhesin”
  • such a fusion could be to the Fc region of an IgG molecule.
  • the Ig fusions preferably include the substitution of a soluble (transmembrane domain deleted or inactivated) form of a PROl 79, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide in place of at least one variable region within an Ig molecule.
  • the immunoglobulin fusion includes the hinge, CH2 and CH3 , or the hinge, CHI, CH2 and CH3 regions of an IgGl molecule.
  • PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 by culturing cells transformed or transfected with a vector containing PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 nucleic acid.
  • the PR0179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide sequence, or portions thereof may be produced by direct peptide synthesis using solid-phase techniques [see, e.g., Stewart etal, Solid-Phase Peptide Synthesis. W.H.
  • In vitro protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions.
  • PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide.
  • DNA encoding PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 may be obtained from a cDNA library prepared from tissue believed to possess the PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 mRNA and to express it at a detectable level.
  • human PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 DNA can be conveniently obtained from a cDNA library prepared from human tissue, such as described in the Examples.
  • the PR0179-, PRO207-, PRO320-, PR0219-, PR0221-, PR0224-, PR0328-, PRO301-, PR0526-, PR0362-, PR0356-, PRO509- or PR0866-encoding gene may also be obtained from a genomic library or by known synthetic procedures (e.g., automated nucleic acid synthesis). Libraries can be screened with probes (such as antibodies to the PRO 179, PRO207, PRO320, PR0219,
  • PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 is to use PCR methodology [Sambrook et al, supra; Dieffenbach et al, PCR Primer: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1995)].
  • the oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized.
  • the oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened. Methods of labeling are well known in the art, and include the use of radiolabels like 32 P-labeled ATP, biotinylation or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook et al, supra.
  • Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined using methods known in the art and as described herein.
  • Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook et al, supra, to detect precursors and processing intermediates of mRNA that may not have been reverse-transcribed into cDNA.
  • Host cells are transfected or transformed with expression or cloning vectors described herein for PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
  • the culture conditions such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach. M. Butler, ed. (IRL Press, 1991) and Sambrook et al, supra.
  • Methods of eukaryotic cell transfection and prokaryotic cell transformation are known to the ordinarily skilled artisan, for example, CaCl 2 , CaP0 4 , liposome-mediated and electroporation. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells.
  • the calcium treatment employing calcium chloride, as described in Sambrook et al, supra, or electroporation is generally used for prokaryotes.
  • Infection with Agrobacterium tumefaciens is used for transformation of certain plant cells, as described by Shaw et al, Gene, 23:315 (1983) and WO 89/05859 published 29 June 1989.
  • Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells
  • Suitable prokaryotes include but are not limited to eubacte ⁇ a, such as Gram-negative or Gram-positive organisms, for example, Enterobacte ⁇ aceae such as E coli
  • E coli strains are publicly available, such as £ coli K12 strain MM294 (ATCC 31 ,446), E coli XI 776 (ATCC 31, 537), E coli strain W31 10 (ATCC 27,325) and K5 772 (ATCC 53,635)
  • Other suitable prokaryotic host cells include Enterobacte ⁇ aceae such as Escherichia, e g ,E colt, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e g , Salmonella typhimurium, Serratia, e g , Serratia marc
  • eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for PR0179-, PRO207-, PRO320-, PR0219-, PR0221-, PR0224-, PR0328-, PRO301-, PR0526-, PR0362-, PR0356-, PRO509- or PR0866-encod ⁇ ng vectors
  • Saccharomyces cerevisiae is a commonly used lower eukaryotic host microorganism Others include Schizosaccharomycespombe (Beach and Nurse, Nature,
  • Kluyveromyces hosts such as, e g , K l ⁇ ctis (MW98-8C, CBS683, CBS4574, Louvencourt et ⁇ l , J Bactenol .
  • K fr ⁇ g ⁇ s ATCC 12,424), K bulg ⁇ rtcus (ATCC 16,045), K wicker ⁇ mn (ATCC 24,178), A: w ⁇ ltu (ATCC 56,500), K drosoph ⁇ rum (ATCC 36,906, Van den Berg et ⁇ l , Bio/Technology. 8 135
  • Methylotropic yeasts are suitable herein and include, but are not limited to. yeast capable of growth on methanol selected from the genera consisting of Hansenula, Candida, Kloeckera, Pichia, Saccharomyces, Torulopsis, and Rhodotorula. A list of specific species that are exemplary of this class of yeasts may be found in C. Anthony, The Biochemistry of Methylotrophs, 269 ( 1982). Suitable host cells for the expression of glycosylated PRO 179, PRO207, PRO320, PR0219, PR0221,
  • PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 are derived from multicellular organisms.
  • invertebrate cells include insect cells such as Drosophila S2 and Spodoptera Sf9, as well as plant cells.
  • useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney C V 1 line transformed by S V40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al, J. Gen. Virol.. 36:59(1977)); Chinese hamster ovary cellsADHFR (CHO, Urlaub and Chasin, Proc.
  • mice sertoli cells TM4, Mather, Biol. Reprod.. 23:243-251 (1980)
  • human lung cells W138, ATCC CCL 75
  • human liver cells Hep G2, HB 8065
  • mouse mammary tumor MMT 060562, ATCC CCL51 .
  • the selection of the appropriate host cell is deemed to be within the skill in the art.
  • the nucleic acid (e.g., cDNA or genomic DNA)encoding PRO179, PRO207, PRO320,PRO219,PRO221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression.
  • a replicable vector for cloning (amplification of the DNA) or for expression.
  • Various vectors are publicly available.
  • the vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage.
  • the appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art.
  • Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques which are known to the skilled artisan.
  • PR0356, PRO509 or PRO866 may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide.
  • the signal sequence may be a component of the vector, or it may be a part of the PROl 79-, PRO207-, PRO320-, PR0219-, PR0221-, PR0224-, PR0328-, PRO301-, PR0526-, PR0362-, PR0356-, PRO509- or PR0866-encoding DNA that is inserted into the vector.
  • the signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders.
  • the signal sequence may be, e.g., the yeast invertase leader, alpha factor leader (including Saccharomyces and Kluyveromyces ⁇ -factor leaders, the latter described in U.S. Patent No.5,010,182), or acid phosphatase leader, the C. albicans glucoamylase leader (EP 362, 179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990.
  • mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.
  • Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses.
  • the origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 ⁇ plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells.
  • Selection genes will typically contain a selection gene, also termed a selectable marker.
  • Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli.
  • selectable markers for mammalian cells are those that enable the identification of cells competent to take up the PRO 179-, PRO207-, PRO320-, PR0219-, PR0221 -, PR0224-, PR0328-, PRO301 -, PR0526-, PR0362-, PR0356-, PRO509- or PR0866-encoding nucleic acid, such as DHFR or thymidine kinase.
  • An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al, Proc. Natl. Acad. Sci. USA, 77:4216 (1980).
  • a suitable selection gene for use in yeast is the trp 1 gene present in the yeast plasmid YRp7 [Stinchcomb et al, Nature.282:39 ( 1979); Kingsman et al. Gene, 7:141 (1979); Tschemper et al. Gene, 10:157 (1980)].
  • the trp ⁇ gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 [Jones, Genetics, 85: 12 (1977)].
  • Expression and cloning vectors usually contain a promoter operably linked to the PROl 79-, PRO207-,
  • Promoters suitable for use with prokaryotic hosts include the ⁇ -lactamase and lactose promoter systems [Chang et al, Nature, 275:615 (1978); Goeddel et al, Nature, 281:544 (1979)], alkaline phosphatase, a tryptophan (tip) promoter system [Goeddel, Nucleic Acids Res., 8:4057 (1980); EP 36,776], and hybrid promoters such as the tac promoter [deBoer et al, Proc. Natl. Acad. Sci. USA. 80:21-25 (1983)].
  • Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding PR0179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866.
  • suitable promoting sequences for use with yeast hosts include the promoters for 3- phosphoglycerate kinase [Hitzeman et al, J. Biol. Chem.. 255:2073 ( 1980)] or other glycolytic enzymes [Hess et al, J. Adv.
  • yeast promoters which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase. degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3- phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.
  • PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,21 1 ,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems.
  • viruses such as polyoma virus, fowlpox virus (UK 2,21 1 ,504 published
  • Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, ⁇ -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus.
  • Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.
  • the enhancer may be spliced into the vector at a position 5' or 3' to the PROl 79, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 coding sequence, but is preferably located at a site 5' from the promoter.
  • Expression vectors used in eukaryotic host cells will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regionsof eukaryotic or viral DNAs or cDN As. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding PROl 79, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866.
  • Still other methods, vectors, and host cells suitable for adaptation to the synthesis of PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 in recombinant vertebrate cell culture are described in Gething et al, Nature. 293:620-625 (1981); Mantei et al., Nature. 281:40-46 (1979); EP 117,060; and EP 1 17,058.
  • Gene amplification and/or expression may be measured in a sample directly, for example, by conventional
  • duplexes including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes.
  • the antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.
  • Gene expression may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product.
  • Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal.
  • the antibodies may be prepared against a native sequence PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 DNA and encoding a specific antibody epitope.
  • PROl 79, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g., Triton-X 100) or by enzymatic cleavage. Cells employed in expression of PRO 179, PRO207, PRO320, PR0219, PR0221,
  • PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents.
  • the following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind epitope- tagged forms of the PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866.
  • Some drug candidates for use in the compositions and methods of the present invention are antibodies and antibody fragments which mimic the biological activity of a PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide.
  • Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant.
  • the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections.
  • the immunizing agent may include the PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide or a fusion protein thereof.
  • immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor.
  • adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).
  • the immunization protocol may be selected by one skilled in the art without undue experimentation.
  • the antibodies may, alternatively, be monoclonal antibodies.
  • Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 ( 1975).
  • a hybridoma method a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent.
  • the lymphocytes may be immunized in vitro.
  • the immunizingagent will typically include the PRO 179, PRO207, PRO320, PR0219, PR0221 ,PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide or a fusion protein thereof.
  • PBLs peripheral blood lymphocytes
  • spleen cells or lymph node cells are used if non-human mammalian sources are desired.
  • the lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, ( 1986) pp.
  • Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed.
  • the hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells.
  • a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells.
  • the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT)
  • HGPRT or HPRT hypoxanthine guanine phosphoribosyl transferase
  • the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (“HAT medium”), which substances prevent the growth of HGPRT-deficient cells.
  • Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk
  • the culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866.
  • the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (Rl A) or enzyme-linked immunoabsorbent assay (ELISA).
  • Rl A radioimmunoassay
  • ELISA enzyme-linked immunoabsorbent assay
  • the binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem.. 107:220 (1980).
  • the clones may be subcloned by limiting dilution procedures and grown by standard methods [Goding, supra]. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI- 1640 medium. Alternatively, the hybridoma cells may be grown in vivo as ascites in a mammal.
  • the monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purificationproceduressuch as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
  • immunoglobulin purificationprocedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
  • the monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567.
  • DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies).
  • the hybridoma cells of the invention serve as a preferred source of such DNA.
  • the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.
  • the DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences [U.S. Patent No.4,816,567; Morrison et al, supra] or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide.
  • non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.
  • the antibodies may be monovalent antibodies.
  • Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain.
  • the heavy chain is truncated generally at any point in the Fc region so as to prevent heavy chain crosslinking.
  • the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking.
  • the antibodies of the invention may further comprise humanized antibodies or human antibodies.
  • Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab'), or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin.
  • Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
  • CDR complementary determining region
  • Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
  • the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al, Nature, 321 :522-525 (1986); Riechmann et al, Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol.. 2:593-596 (1992)].
  • Fc immunoglobulin constant region
  • a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non- human amino acid residues are often referred to as "import" residues, which are typically taken from an "import” variable domain.
  • Humanization can be essentially performed following the method of Winter and co-workers [Jones et al, Nature, 321:522-525 (1986); Riechmann et al, Nature, 332:323-327 (1988); Verhoeyen et al, Science.239: 1534- 1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody.
  • humanized antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
  • humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
  • Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol.. 227:381 (1991); Marks et al, J. Mol. Biol.. 222:581 (1991)].
  • the techniques of Cole et al, and Boerner et al, are also available for the preparation of human monoclonal antibodies (Cole et al. Monoclonal Antibodies and Cancer Therapy. Alan R. Liss, p. 77 (1985) and Boerner et al, J. Immunol.. 147(l):86-95 (1991)].
  • human antibodies can be made by the introducing of human immunoglobulin loci into transgenic animals, e.g.
  • mice in which the endogenous immunoglobulin genes have been partially or completely inactivated Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire.
  • This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al, Bio/Technology, 10: 779-783 (1992); Lonberge/ al, Nature, 368: 856-859 ( 1994); Morrison, Nature.368: 812-13 (1994); Fishwild e. al, Nature Biotechnology.14:845-51 ( 1996); Neuberger, Nature Biotechnology, H: 826 ( 1996); Lonberg and Huszar, Intern. Rev. Immunol.. 3 :65-93 (1995).
  • Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for the PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit. Methods for making bispecific antibodies are known in the art.
  • bispecific antibodies are based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities [Milstein and Cuello, Nature. 305:537-539 (1983)]. Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture often different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker e. ⁇ /.. EMBO J cohesive 10:3655-3659 (1991 ).
  • Antibody variable domains with the desired binding specificities can be fused to immunoglobulin constant domain sequences.
  • the fusion preferably is with an immunoglobulin heavy- chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CHI) containing the site necessary for light-chain binding present in at least one of the fusions.
  • CHI first heavy-chain constant region
  • the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture.
  • the preferred interface comprises at least a part of the CH3 region of an antibody constant domain.
  • one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan).
  • Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g., alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.
  • Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g., F(ab') 2 bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al. , Science, 229: 81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab') 2 fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives.
  • TAB thionitrobenzoate
  • One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody.
  • the bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.
  • Fab' fragments may be directly recovered from E. coli and chemically coupled to form bispecific antibodies.
  • Shalaby et al, J. Exp. Med., 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab'), molecule.
  • Each Fab' fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to form the bispecific antibody.
  • the bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.
  • bispecific antibodies have been produced using leucine zippers.
  • the leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion.
  • the antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers.
  • the "diabody” technology described by Hollinger et al, Proc. Natl. Acad. Sci. USA.
  • the fragments comprise a heavy-chain variable domain (V H ) connected to a light-chain variable domain (V L ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V H and V L domains of one fragment are forced to pair with the complementary V L and V H domains of another fragment, thereby forming two antigen-binding sites.
  • V H and V L domains of one fragment are forced to pair with the complementary V L and V H domains of another fragment, thereby forming two antigen-binding sites.
  • sFv single-chain Fv
  • Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al , J. Immunol., 152:5368 (1994'). Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al. , J. Immunol.. 147:60 (
  • Exemplary bispecific antibodies may bind to two different epitopes on a given PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide herein.
  • an anti-PRO 179, anti-PRO207, anti-PRO320, anti-PR0219, anti-PR0221 , anti- PR0224, anti-PR0328, anti-PRO301, anti-PR0526, anti-PR0362, anti-PR0356, anti-PRO509 or anti-PR0866 polypeptide arm may be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g.
  • Fc receptors for IgG Fc ⁇ R
  • Fc ⁇ R Fc receptors for IgG
  • Fc ⁇ Rl CD64
  • Fc ⁇ RII CD32
  • Fc ⁇ RIII CD 16
  • Bispecific antibodies may also be used to localize cytotoxic agents to cells which express a particular PROl 79, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide.
  • These antibodies possess a PROl 79-, PRO207-, PRO320-, PR0219-, PR0221 -, PR0224-, PR0328-, PRO301 -,PR0526-, PR0362-, PR0356-, PRO509- or PR0866-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA.
  • a radionuclide chelator such as EOTUBE, DPTA, DOTA, or TETA.
  • Another bispecific antibody of interest binds the PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide and further binds tissue factor (TF).
  • tissue factor TF
  • Heteroconjugate antibodies are also within the scope of the present invention.
  • Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells [U.S. Patent No. 4,676,980], and for treatment of HIV infection [WO 91/00360; WO 92/200373; EP 03089].
  • the antibodies may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents.
  • immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.
  • cysteine residue(s) may be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region.
  • the homodimeric antibody thus generated may have improved internalization capability and/or increased complement- mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See, Caron et al, J. Exp. Med.. 176: 1 191-1 195 (1992) and Shopes, J. Immunol.. 148: 2918-2922 ( 1992).
  • Homodimeric antibodies with enhanced antitumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff et al, Cancer Research. 53: 2560-2565 (1993).
  • an antibody can be engineered that has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See, Stevenson et al. , Anti-Cancer Drug Design. 3: 219-230 (1989).
  • the invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).
  • a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).
  • Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes.
  • a variety of radionuclides are available for the production of radioconjugated antibodies. Examples include 2l2 Bi, 13 I I, l3 l In, 90 Y, and ,86 Re.
  • Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such asN-succinimidyl-3-(2-pyridyldithiol)propionate(SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis- active fluorine compounds (such as l,5-difluoro-2,4-dinitrobenzene).
  • bifunctional protein-coupling agents such asN-
  • a ricin immunotoxin can be prepared as described in Vitetta et al, Science. 238: 1098(1987).
  • Carbon- 14-labeled l-isothiocyanatobenzyl-3- methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See, W094/1 1026.
  • the antibody may be conjugated to a "receptor” (such as streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand” (e.g., avidin) that is conjugated to a cytotoxic agent (e.g., a radionucleotide).
  • a "receptor” such as streptavidin
  • a ligand e.g., avidin
  • cytotoxic agent e.g., a radionucleotide
  • the antibodies disclosed herein may also be formulated as immunoliposomes.
  • Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al, Proc. Natl. Acad. Sci. USA. 82: 3688 (1985); Hwang et al, Proc. Natl. Acad. Sci. USA. 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.
  • Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG- PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter.
  • Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al, J. Biol. Chem.. 257: 286-288 (1982) via a disulfide-interchange reaction.
  • a chemotherapeutic agent such as Doxorubicin is optionally contained within the liposome. See, Gabizon et al, J. National Cancer Inst, 81(19): 1484 (1989).
  • NCI National Cancer Institute
  • cell-based assays and animal models for tumors can also be used to verify the findings of the NCI cancer screen, and to further understand the relationship between the protein identified herein and the development and pathogenesis of neoplastic cell growth.
  • primary cultures derived from tumors in transgenic animals as described below can be used in the cell-based assays herein, although stable cell lines are preferred. Techniques to derive continuous cell lines from transgenic animals are well known in the art (see, e.g., Small et al., Mol. Cell. Biol.. 5:642-648 [1985]).
  • Animal Models A variety of well known animal models can be used to further understand the role of the molecules identified herein in the development and pathogenesis of tumors, and to test the efficacy of candidate therapeutic agents, including antibodies, and other agonists of the native polypeptides, including small molecule agonists. The in vivo nature of such models makes them particularly predictive of responses in human patients.
  • Animal models of tumors and cancers e.g., breast cancer, colon cancer, prostate cancer, lung cancer, etc.
  • Non-recombinant animal models include, for example, rodent, e.g., murine models.
  • Such models can be generated by introducing tumor cells into syngeneic mice using standard techniques, e.g., subcutaneous injection, tail vein injection, spleen implantation, intraperitoneal implantation, implantation under the renal capsule, or orthopin implantation, e.g., colon cancer cells implanted in colonic tissue.
  • standard techniques e.g., subcutaneous injection, tail vein injection, spleen implantation, intraperitoneal implantation, implantation under the renal capsule, or orthopin implantation, e.g., colon cancer cells implanted in colonic tissue.
  • the autosomal recessive nu gene has been introduced into a very large number of distinct congenic strains of nude mouse, including, for example, ASW, A/He, AKR, BALB/c, B10.LP, C17, C3H, C57BL, C57, CBA, DBA, DDD, I/st, NC, NFR, NFS, NFS/N, NZB, NZC, NZW, P, RIII and SJL.
  • a wide variety of other animals with inherited immunological defects other than the nude mouse have been bred and used as recipients of tumor xenografts. For further details see, e.g. , The Nude Mouse in Oncology Research. E. Boven and B. Winograd, eds., CRC Press, Inc., 1991.
  • the cells introduced into such animals can be derived from known tumor/cancer cell lines, such as, any of the above-listed tumor cell lines, and, for example, the B104-1-1 cell line (stable NIH-3T3 cell line transfected with the neu protooncogene); ras-transfected NIH-3T3 cells; Caco-2 (ATCC HTB-37); a moderately well- differentiated grade II human colon adenocarcinoma cell line, HT-29 (ATCC HTB-38), or from tumors and cancers.
  • Samples of tumor or cancer cells can be obtained from patients undergoing surgery, using standard conditions, involving freezing and storing in liquid nitrogen (Karmali et al, Br. J. Cancer, 48:689-696 [1983]).
  • Tumor cells can be introduced into animals, such as nude mice, by a variety of procedures.
  • the subcutaneous (s.c.) space in mice is very suitable for tumor implantation.
  • Tumors can be transplanted s.c. as solid blocks, as needle biopsies by use of a trochar, or as cell suspensions.
  • tumor tissue fragments of suitable size are introduced into the s.c. space.
  • Cell suspensions are freshly prepared from primary tumors or stable tumor cell lines, and injected subcutaneously.
  • Tumor cells can also be injected as subdermal implants. In this location, the inoculum is deposited between the lower part of the dermal connective tissue and the s.c. tissue. Boven and Winograd ( 1991 ), supra.
  • Animal models of breast cancer can be generated, for example, by implanting rat neuroblastoma cells (from which the neu oncogen was initially isolated), or neu- transformed NIH-3T3 cells into nude mice, essentially as described by Drebin et al, Proc. Natl. Acad. Sci. USA. 83:9129-9133 (1986).
  • animal models of colon cancer can be generated by passaging colon cancer cells in animals, e.g. , nude mice, leading to the appearance of tumors in these animals.
  • An orthotopic transplant model of human colon cancer in nude mice has been described, for example, by Wang et al. Cancer Research, 54:4726-4728 (1994) and Too et al. , Cancer Research, 55:681 -684 ( 1995). This model is based on the so-called “METAMOUSE” sold by AntiCancer, Inc., (San Diego, California).
  • Tumors that arise in animals can be removed and cultured in vitro. Cells from the in vitro cultures can then be passaged to animals. Such tumors can serve as targets for further testing or drug screening. Alternatively, the tumors resulting from the passage can be isolated and RNA from pre-passage cells and cells isolated after one or more rounds of passage analyzed for differential expression of genes of interest. Such passaging techniques can be performed with any known tumor or cancer cell lines.
  • Meth A, CMS4, CMS5, CMS21 , and WEHI-164 are chemically induced fibrosarcomas of BALB/c female mice (DeLeo et al, J. Exp. Med.. 146:720 [1977]), which provide a highly controllable model system for studying the anti-tumor activities of various agents (Palladino et al, J. Immunol.. 138:4023-4032
  • tumor cells are propagated in vitro in cell culture. Prior to injection into the animals, the cell lines are washed and suspended in buffer, at a cell density of about lOxlO 6 to lOxl O 7 cells/ml. The animals are then infected subcutaneously with 10 to 100 ⁇ l of the cell suspension, allowing one to three weeks for a tumor to appear.
  • the Lewis lung (3LL) carcinoma of mice which is one of the most thoroughly studied experimental tumors, can be used as an investigational tumor model. Efficacy in this tumor model has been correlated with beneficial effects in the treatment of human patients diagnosed with small cell carcinoma of the lung (SCCL).
  • SCCL small cell carcinoma of the lung
  • This tumor can be introduced in normal mice upon injection of tumor fragments from an affected mouse or of cells maintained in culture (Zupi et al, Br. J. Cancer. 41 , suppl. 4:309 [1980]), and evidence indicates that tumors can be started from injection of even a single cell and that a very high proportion of infected tumor cells survive. For further information about this tumor model see, Zacharski, Haemostasis, 16_:300-320 [1986]).
  • One way of evaluating the efficacy of a test compound in an animal model is implanted tumor is to measure the size of the tumor before and after treatment.
  • the size of implanted tumors has been measured with a slide caliper in two or three dimensions.
  • the measure limited to two dimensions does not accurately reflect the size of the tumor, therefore, it is usually converted into the corresponding volume by using a mathematical formula.
  • the measurement of tumor size is very inaccurate.
  • the therapeutic effects of a drug candidate can be better described as treatment-induced growth delay and specific growth delay.
  • Another important variable in the description of tumor growth is the tumor volume doubling time.
  • Computer programs for the calculation and description of tumor growth are also available, such as the program reported by Rygaard and Spang-Thomsen, Proc. 6th Int.
  • necrosis and inflammatory responses following treatment may actually result in an increase in tumor size, at least initially. Therefore, these changes need to be carefully monitored, by a combination of a morphometric method and flow cytometric analysis.
  • Recombinant (transgenic) animal models can be engineered by introducing the coding portion of the genes identified herein into the genome of animals of interest, using standard techniques for producing transgenic animals.
  • Animals that can serve as a target for transgenic manipulation include, without limitation, mice, rats, rabbits, guinea pigs, sheep, goats, pigs, and non-human primates, e.g., baboons, chimpanzees and monkeys.
  • Techniques known in the art to introduce a transgene into such animals include pronucleic microinjection (Hoppe and Wanger, U.S. Patent No. 4,873,191); retrovirus-mediated gene transfer into germ lines (e.g., Van der Putten et al, Proc. Natl.
  • transgenic animals include those that carry the transgene only in part of their cells ("mosaic animals").
  • the transgene can be integrated either as a single transgene, or in concatamers, e.g.
  • transgenes into a particular cell type are also possible by following, for example, the technique of Lasko et al. Proc. Natl. Acad. Sci. USA. 89:6232- 636 (1992).
  • the expression of the transgene in transgenic animals can be monitored by standard techniques. For example, Southern blot analysis or PCR amplification can be used to verify the integration of the transgene.
  • the level of mRNA expression can then be analyzed using techniques such as in situ hybridization, Northern blot analysis, PCR, or immunocytochemistry. The animals are further examined for signs of tumor or cancer development.
  • SCC feline oral squamous cell carcinoma
  • Feline oral SCC is a highly invasive, malignant tumor that is the most common oral malignancy of cats, accounting for over 60% of the oral tumors reported in this species. It rarely metastasizes to distant sites, although this low incidence of metastasis may merely be a reflection of the short survival times for cats with this tumor.
  • These tumors are usually not amenable to surgery, primarily because of the anatomy of the feline oral cavity. At present, there is no effective treatment for this tumor.
  • each cat Prior to entry into the study, each cat undergoes complete clinical examination, biopsy, and is scanned by computed tomography (CT). Cats diagnosed with sublingual oral squamous cell tumors are excluded from the study. The tongue can become paralyzed as a result of such tumor, and even if the treatment kills the tumor, the animals may not be able to feed themselves.
  • CT computed tomography
  • Each cat is treated repeatedly, over a longer period of time. Photographs of the tumors will be taken daily during the treatment period, and at each subsequent recheck.
  • CT scans and thoracic radiograms are evaluated every 8 weeks thereafter. The data are evaluated for differences in survival, response and toxicity as compared to control groups. Positive response may require evidence of tumor regression, preferably with improvement of quality of life and/or increased life span.
  • fibrosarcoma adenocarcinoma
  • lymphoma adenocarcinoma
  • chrondroma adenocarcinoma of dogs, cats
  • baboons a preferred model as its appearance and behavior are very similar to those in humans.
  • the use of this model is limited by the rare occurrence of this type of tumor in animals.
  • Screening assays for drug candidates are designed to identify compounds that competitively bind or complex with the receptor(s) of the polypeptides identified herein, or otherwise signal through such receptor(s).
  • Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates.
  • Small molecules contemplated include synthetic organic or inorganic compounds, including peptides, preferably soluble peptides, (poly)peptide- immunoglobulin fusions, and, in particular, antibodies including, without limitation, poly- and monoclonal antibodies and antibody fragments, single-chain antibodies, anti-idiotypic antibodies, and chimeric or humanized versions of such antibodies or fragments, as well as human antibodies and antibody fragments.
  • the assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays and cell based assays, which are well characterized in the art.
  • a receptor of a polypeptide encoded by the gene identified herein or the drug candidate is immobilized on a solid phase, e.g., on a microtiter plate, by covalent or non-covalent attachments.
  • Non-covalent attachment generally is accomplished by coating the solid surface with a solution of the polypeptide and drying.
  • an immobilized antibody e.g., a monoclonal antibody, specific for the polypeptide to be immobilized can be used to anchor it to a solid surface.
  • the assay is performed by adding the non-immobilized component, which may be labeled by a detectable label, to the immobilized component, e.g., the coated surface containing the anchored component.
  • the non-reacted components are removed, e.g., by washing, and complexes anchored on the solid surface are detected.
  • the detection of label immobilized on the surface indicates that complexing occurred.
  • complexing can be detected, for example, by using a labeled antibody specifically binding the immobilized complex.
  • the candidate compound interacts with but does not bind to a particular receptor, its interaction with that polypeptide can be assayed by methods well known for detecting protein-protein interactions.
  • assays include traditional approaches, such as, cross-linking, co-immunoprecipitation, and co-purification through gradients or chromatographic columns.
  • protein-protein interactions can be monitored by using a yeast-based genetic system described by Fields and co-workers [Fields and Song, Nature (London), 340:245-246 ( 1989); Chien et al, Proc. Natl. Acad. Sci. USA. 88:9578-9582 (1991)1 as disclosed by Chevrav and Nathans [Proc. Natl. Acad. Sci. USA.
  • yeast GAL4 Many transcriptional activators, such as yeast GAL4, consist of two physically discrete modular domains, one acting as the DNA-binding domain, while the other one functioning as the transcription activation domain.
  • the yeast expression system described in the foregoing publications (generally referred to as the "two-hybrid system") takes advantage of this property, and employs two hybrid proteins, one in which the target protein is fused to the DNA-binding domain of GAL4, and another, in which candidate activating proteins are fused to the activation domain.
  • the expression of a GAL ⁇ cZ reporter gene under control of a GAL4-activated promoter depends on reconstitution of GAL4 activity via protein-protein interaction.
  • Colonies containing interacting polypeptides are detected with a chromogenic substrate for ⁇ -galactosidase.
  • a complete kit (MATCHMAKERTM) for identifying protein-protein interactions between two specific proteins using the two- hybrid technique is commercially available from Clontech. This system can also be extended to map protein domains involved in specific protein interactions as well as to pinpoint amino acid residues that are crucial forthese interactions.
  • polypeptides of the present invention can be administered for the treatment of tumors, including cancers, in the form of pharmaceutical compositions.
  • peptide molecules can be designed which retain the ability to bind the target protein sequence.
  • Such peptides can be synthesized chemically and or produced by recombinant DNA technology (see, e.g., Marasco et al, Proc. Natl. Acad. Sci. USA. 90:7889-7893 [1993]).
  • the formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
  • the composition may comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent.
  • cytotoxic agent such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent.
  • Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
  • Therapeutic formulations of the polypeptides identified herein, or agonists thereof are prepared for storage by mixing the active ingredient having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (Reminston's Pharmaceutical Sciences. 16th edition, Osol, A. ed. [1980]), in the form of lyophilized formulations or aqueous solutions.
  • Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzy 1 ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine,
  • the formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
  • the composition may comprise a cytotoxic agent, cytokine or growth inhibitory agent.
  • cytotoxic agent cytokine or growth inhibitory agent.
  • Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
  • the active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.
  • colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
  • compositions to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution.
  • Therapeutic compositions herein generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
  • Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No.
  • copolymers of L-glutamic acid and ⁇ ethyl-L-glutamate copolymers of L-glutamic acid and ⁇ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOTTM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.
  • encapsulated antibodies When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.
  • the polypeptides of the present invention and their agonists may be used to treat various tumors, e.g. , cancers.
  • exemplary conditions or disorders to be treated include benign or malignant tumors (e.g., renal, liver, kidney, bladder, breast, gastric, ovarian, colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic carcinomas; sarcomas; glioblastomas; and various head and neck tumors); leukemias and lymphoid malignancies; other disorders such as neuronal, glial, astrocytal, hypothalamic and other glandular, macrophagal, epithelial, stromal and blastocoelic disorders; and inflammatory, angiogenic and immunologic disorders.
  • benign or malignant tumors e.g., renal, liver, kidney, bladder, breast, gastric, ovarian, colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic carcinomas; sar
  • the anti-tumor agents of the present invention are administered to a mammal, preferably a human, in accord with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time, or by intramuscular, intraperitoneal,intracerobrospinal,intraocular, intraarterial, intralesional,subcutaneous,intraarticular,intrasynovial, intrathecal, oral, topical, or inhalation routes.
  • chemotherapeutic agents may be administered to the patient. Preparation and dosing schedules for such chemotherapeutic agents may be used according to manufacturers' instructions or as determined empirically by the skilled practitioner. Preparation and dosing schedules for such chemotherapy are also described in Chemotherapy Service, ed., M.C. Perry, Williams & Wilkins, Baltimore, MD (1992). The chemotherapeutic agent may precede, or follow administration of the anti-tumor agent of the present invention, or may be given simultaneously therewith.
  • the anti-cancer agents of the present invention may be combined with an anti-oestrogen compound such as tamoxifen or an anti-progesterone such as onapristone (see, EP 616812) in dosages known for such molecules.
  • the anti-cancer agents herein are co-administered with a growth inhibitory agent.
  • the growth inhibitory agent may be administered first, followed by the administration of an anti-cancer agent of the present invention.
  • simultaneous administration or administration of the anti-cancer agent of the present invention first is also contemplated. Suitable dosages for the growth inhibitory agent are those presently used and may be lowered due to the combined action (synergy) of the growth inhibitory agent and the antibody herein.
  • an anti-tumor agent for the prevention or treatment of disease, will depend on the type of disease to be treated, as defined above, the severity and course of the disease, whether the agent is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the agent, and the discretion of the attending physician.
  • the agent is suitably administered to the patient at one time or over a series of treatments. Animal experiments provide reliable guidance for the determination of effective doses for human therapy. Interspecies scaling of effective doses can be performed following the principles laid down by Mordenti, J. and Chappell, W. "The use of interspecies scaling in toxicokinetics" in Toxicokinetics and New Drug Development. Yacobi et al, eds., Pergamon Press, New York 1989, pp. 42-96.
  • an antitumor agent is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion.
  • a typical daily dosage might range from about 1 g/kg to 100 mg/kg or more, depending on the factors mentioned above.
  • the treatment is sustained until a desired suppression of disease symptoms occurs.
  • other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays. Guidance as to particular dosages and methods of delivery is provided in the literature; see, for example, U.S. Pat.
  • an article of manufacture containing materials useful for the diagnosis or treatment of the disorders described above comprises a container and a label.
  • Suitable containers include, for example, bottles, vials, syringes, and test tubes.
  • the containers may be formed from a variety of materials such as glass or plastic.
  • the container holds a composition which is effective for diagnosing or treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
  • the active agent in the composition is an anti-tumor agent of the present invention.
  • the label on, or associated with, the container indicates that the composition is used for diagnosing or treating the condition of choice.
  • the article of manufacture may further comprise a second container comprising a pharmaceutically- acceptable buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.
  • a pharmaceutically- acceptable buffer such as phosphate-buffered saline, Ringer's solution and dextrose solution.
  • It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.
  • EXAMPLES Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Col lection, Manassas, VA. EXAMPLE 1 : Extracellular Domain Homology Screening to Identify Novel Polypeptides and cDNA Encoding
  • the extracellular domain (ECD) sequences (including the secretion signal sequence, if any) from about 950 known secreted proteins from the Swiss-Prot public database were used to search EST databases.
  • the EST databases included public databases (e.g., Dayhoff, GenBank), and proprietary databases (e.g. LIFESEQ ® , Incyte Pharmaceuticals, Palo Alto, CA).
  • the search was performed using the computer program BLAST or BLAST-2 (Altschul et al. , Methods in Enzymology, 266:460-480 (1996)) as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequences. Those comparisons with a BLAST score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into consensus DNA sequences with the program "phrap” (Phil Green, University of Washington, Seattle, Washington).
  • Forward and reverse PCR primers generally range from 20 to 30 nucleotides and are often designed to give a PCR product of about 100- 1000 bp in length.
  • the probe sequences are typically 40-55 bp in length.
  • additional oligonucleotides are synthesized when the consensus sequence is greater than about 1-1.5 kbp.
  • DNA from the libraries was screened by PCR amplification, as per Ausubel et al. , Current Protocols in Molecular Biology, with the PCR primer pair. A positive library was then used to isolate clones encoding the gene of interest using the probe oligonucleotide and one of the primer pairs.
  • the cDNA libraries used to isolate the cDNA clones were constructed by standard methods using commercially available reagents such as those from Invitrogen, San Diego, CA.
  • the cDNA was primed with oligo dT containing a Notl site, linked with blunt to Sail hemikinased adaptors, cleaved with Notl, sized appropriately by gel electrophoresis, and cloned in a defined orientation into a suitable cloning vector (such as pRKB or pRKD; pRK5B is a precursor of pRK5D that does not contain the Sfil site; see, Holmes et al, Science, 253:1278-1280 (1991)) in the unique Xhol and Notl sites.
  • a suitable cloning vector such as pRKB or pRKD; pRK5B is a precursor of pRK5D that does not contain the Sfil site; see, Holmes et al, Science, 25
  • cDNA clone (DNA16451-1078) encoding a native human PRO 179 polypeptide was identified using a yeast screen, in a human fetal liver library that preferentially represents the 5' ends of the primary cDNA clones.
  • the primers used for the identification of DNA16451-1078 are as follows: OLI1 14:
  • Clone DNA 16451 - 1078 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 37-39, and an apparent stop codon at nucleotide positions 1417-1419 ( Figures 1 ; SEQ ID NO: l).
  • the predicted polypeptide precursor is 460 amino acids long.
  • the full-length PRO 179 protein is shown in Figure 2 (SEQ ID NO:2).
  • TIE is an acronym which stands for "tyrosine kinase containing Ig and EGF homology domains" and was coined to designate a new family of receptor tyrosine kinases. Accordingly, PRO 179 has been identified as a novel member of the TIE ligand family.
  • EST DNA database (LIFESEQ ® , Incyte Pharmaceuticals, Palo Alto, CA) was searched and an EST was identified which showed homology to human Apo-2 ligand.
  • a human fetal kidney cDNA library was then screened.
  • mRNAisolated from human fetal kidney tissue (Clontech) was used to prepare the cDNA library. This RNA was used to generate an oligo dT primed cDNA library in the vector pRK5D using reagents and protocols from Life Technologies, Gaithersburg, MD (Super Script Plasmid System).
  • the double stranded cDNA was sized to greater than 1000 bp and the Sall/Notl linkered cDNA was cloned into Xhol/Notl cleaved vector.
  • pRK5D is a cloning vector that has an sp6 transcription initiation site followed by an Sfil restriction enzyme site preceding the Xhol/Notl cDNA cloning sites.
  • the library was screened by hybridization with a synthetic oligonucleotide probe:
  • a cDNA clone was sequenced in entirety.
  • a nucleotide sequence of the full-length DNA30879-1 152 is shown in Figure 3 (SEQ ID NO:6).
  • Clone DNA30879- 1152 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 58-60 ( Figure 3; SEQ ID NO:6) and an apparent stop codon at nucleotide positions 805-807.
  • the predicted polypeptide precursor is 249 amino acids long.
  • Clone DNA30879-1 152 has been deposited with ATCC on October 10, 1997 and is assigned ATCC deposit no. 209358.
  • the full-length PRO207 protein shown in Figure 4 has an estimated molecular weight of about 27,216 daltons and a pi of about 9.61.
  • PRO207 shows amino acid sequence identity to several members of the TNF cytokine family, and particularly, to human lymphotoxin-beta (23.4%) and human CD40 ligand (19.8%).
  • DNA28739 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is designated herein as DNA28739. Based on the
  • DNA28739 consensus sequence oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for
  • PRO320 A pair of PCR primers (forward and reverse) were synthesized: forward PCR primer:
  • hybridization probe 5'-GATAAACTGTCAGTACAGCTGTGAAGACACAGAAGAAGGGCCACAGTGCC-3' (SEQ ID NO: 13)
  • RNA for construction of the cDNA libraries was isolated from human fetal lung tissue (LIB025).
  • a signal peptide from about amino acid 1 to about amino acid 21 ; an amidation site from about amino acid 330 to about amino acid 334; aspartic acid and asparagine hydroxylation sites from about amino acid 109 to about amino acid 121 , from about amino acid 191 to about amino acid 203, and from about amino acid 236 to about amino acid 248; an EGF-like domain cysteine pattern signature from about amino acid 80 to about amino acid 91 ; calcium-binding EGF-like domains from about amino acid 103 to about amino acid 125, from about amino acid 230 to about amino acid 252, and from about amino acid 185 to about amino acid 207.
  • EXAMPLE 5 Isolation of cDNA clones Encoding Human PRQ219 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is designated herein as DNA28729. Based on the DNA28729 consensus sequence, oligonucleotides were synthesized: 1 ) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PR0219.
  • forward PCR primer A pair of PCR primers (forward and reverse) were synthesized: forward PCR primer:
  • hybridization probe 5'-GCCTGTCAGTGTCCTGAGGGACACGTGCTCCGCAGCGATGGGAAG-3' (SEQ ID NO: 18)
  • RNA for construction of the cDNA libraries was isolated from human fetal kidney tissue.
  • DNA sequencing of the isolated clones isolated as described above gave the full-length DNA sequence for DNA32290-1 164 [ Figure 7, SEQ ID NO: 14]; and the derived protein sequence for PR0219.
  • DNA32290-1 164 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 204-206, and an apparent stop codon at nucleotide positions 2949-2951.
  • the predicted polypeptide precursor is 1005 amino acids long.
  • Analysis of the full-length PR0219 sequence shown in Figure 8 (SEQ ID NO: 15) evidences the presence of a variety of important polypeptide domains, wherein the locations given forthose important polypeptide domains are approximate as described above.
  • a signal peptide from about amino acid 1 to about amino acid 23; an N-glycosylation site from about amino acid 221 to about amino acid 225; cAMP- and cGMP-dependent protein kinase phosphorylation sites from about amino acid 1 15 to about amino acid 1 19, from about amino acid 606 to about amino acid 610, and from about amino acid 892 to about amino acid 896; N- myristoylation sites from about amino acid 133 to about amino acid 139, from about amino acid 258 to about amino acid 264, from about amino acid 299 to about amino acid 305, from about amino acid 340 to about amino acid 346, from about amino acid 453 to about amino acid 459, from about amino acid 494 to about amino acid 500, from about amino acid 639 to about amino acid 645, from about amino acid 690 to about amino acid 694, from about amino acid 752 to about amino acid 758, and from about amino acid 792 to about
  • DNA28756 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is designated herein as DNA28756. Based on the
  • DNA28756 consensus sequence oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PR0221.
  • forward PCR primer A pair of PCR primers (forward and reverse) were synthesized: forward PCR primer:
  • hybridization probe 5'-CACCTGTAGCAATGCAAATCTCAAGGAAATACCTAGAGATCTTCCTCCTG-3' (SEQ ID NO:23)
  • RNA for construction of the cDNA libraries was isolated from human fetal lung tissue.
  • DNA sequencing of the isolated clones isolated as described above gave the full-length DNA sequence for DNA33089-1 132 [ Figure 9, SEQ ID NO: 19]; and the derived protein sequence for PR0221.
  • DNA33089-1 132 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 179-181, and an apparent stop codon at nucleotide positions 956-958.
  • the predicted polypeptide precursor is 259 amino acids long.
  • Analysis of the full-length PR0221 sequence shown in Figure 10 (SEQ ID NO:20) evidences the presence of a variety of important polypeptide domains, wherein the locations given for those important polypeptide domains are approximate as described above.
  • a signal peptide from about amino acid 1 to about amino acid 33; a transmembrane domain from about amino acid 204 to about amino acid 219; N- glycosylation sites from about amino acid 47 to about amino acid 51 and from about amino acid 94 to about amino acid 98; a cAMP- and cGMP-dependent protein kinase phosphorylation site from about amino acid 199 to about amino acid 203; and N-myristoylation sites from about amino acid 37 to about amino acid 43, from about amino acid 45 to about amino acid 51 , and from about amino acid 1 10 to about amino acid 1 16.
  • Clone DNA33089-1 132 has been deposited with the ATCC on September 16, 1997 and is assigned ATCC deposit no. 209262.
  • the full- length PR0221 protein shown in Figure 10 has an estimated molecular weight of about 29,275 daltons and a pi of about 6.92.
  • DNA30845 consensus sequence oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PR0224.
  • forward PCR primer A pair of PCR primers (forward and reverse) were synthesized: forward PCR primer:
  • hybridization probe 5'-GAGGAGGAGTGCAGGATTGAGCCATGTACCCAGAAAGGGCAATGCCCACC-3' (SEQ ID NO:28)
  • RNA for construction of the cDNA libraries was isolated from human fetal liver tissue.
  • DNA33221 -1 133 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 33-35, and an apparent stop codon at nucleotide positions 879-881.
  • the predicted polypeptide precursor is 282 amino acids long.
  • Analysis of the full-length PR0224 sequence shown in Figure 12 evidences the presence of a variety of important polypeptide domains, wherein the locations given for those important polypeptide domains are approximate as described above.
  • a signal peptide from about amino acid 1 to about amino acid 30; a transmembrane domain from about amino acid 231 to about amino acid 248; N- glycosylation sites from about amino acid 126 to about amino acid 130, from about amino acid 195 to about amino acid 199, and from about amino acid 213 to about amino acid 217; N-myristoylation sites from about amino acid 3 to about amino acid 9, from about amino acid 10 to about amino acid 16, from about amino acid 26 to about amino acid 32, from about amino acid 30 to about amino acid 36, from about amino acid 1 12 to about amino acid 1 18, from about amino acid 166 to about amino acid 172, from about amino acid 212 to about amino acid 218, from about amino acid 224 to about amino acid 230, from about amino acid 230 to about amino acid 236, and from about amino acid 263 to about amino acid 269; a prokaryotic membrane lipoprotein lipid attachment site from about amino acid 44 to about amino acid
  • Clone DNA33221-1 133 has been deposited with the ATCC on September 16, 1997 and is assigned ATCC deposit no. 209263.
  • the full-length PR0224 protein shown in Figure 12 has an estimated molecular weight of about 28,991 daltons and a pi of about 4.62.
  • PR0224 has amino acid sequence identity to portions of these proteins in the range from 28% to 45%, and overall identity with these proteins in the range from 33% to 39%.
  • EXAMPLE 8 Isolation of cDNA clones Encoding Human PRQ328 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is designated herein as DNA35615. Based on the DNA35615 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PR0328.
  • forward PCR primer 5'-TCCTGCAGTTTCCTGATGC-3' (SEQ ID NO:31) reverse PCR primer:
  • hybridization probe was constructed from the consensus DNA35615 sequence which had the following nucleotide sequence: hybridization probe:
  • RNA for construction of the cDNA libraries was isolated from human fetal kidney tissue.
  • DNA sequencing of the isolated clones isolated as described above gave the full-length DNA sequence for DNA40587-1231 [ Figure 13, SEQ ID N0:29]; and the derived protein sequence for PR0328.
  • DNA40587-1231 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 15-17, and an apparent stop codon at nucleotide positions 1404-1406.
  • the predicted polypeptide precursor is 463 amino acids long.
  • Analysis of the full-length PR0328 sequence shown in Figure 14 evidences the presence of a variety of important polypeptide domains, wherein the locations given for those important polypeptide domains are approximate as described above.
  • a signal peptide from about amino acid 1 to about amino acid 22; N-glycosylation sites from about amino acid 1 14 to about amino acid 1 18, from about amino acid 403 to about amino acid 407, and from about amino acid 409 to about amino acid 413; a glycosaminoglycan attachment site from about amino acid 439 to about amino acid 443; N-myristoylation sites from about amino acid 123 to about amino acid 129, from about amino acid 143 to about amino acid 149, from about amino acid 152 to about amino acid 158, from about amino acid 169 to about amino acid 175, from about amino acid 180 to about amino acid 186, from about amino acid 231 to about amino acid 237, and from about amino acid 250 to about amino acid 256; amidation sites from about amino acid 82 to about amino acid 88 and from about amino acid 172 to about amino acid 176; a peroxidase proximal heme-ligand signature
  • PR0328 may be a novel glioblastoma protein or cysteine rich secretory protein.
  • SEQ ID NO:30 An analysis of the full-length PR0328sequence shown in Figure 14 (SEQ ID NO:30), suggests that portions of it possess significant homology to the human glioblastoma protein, and to the cysteine rich secretory protein thereby indicating that PR0328 may be a novel glioblastoma protein or cysteine rich secretory protein.
  • EXAMPLE 9 Isolation of cDNA clones Encoding Human PRO301 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is designated herein as DNA35936.
  • oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO301.
  • oligonucleotides used in the above procedure were the following:
  • forward PCR primer 1 5'-TCGCGGAGCTGTGTTCTGTTTCCC-3' (SEQ ID NO:36) forward PCR primer 2:
  • hybridization probe 1 5'-ACTCAGCAGTGGTAGGAAAG-3' (SEQ ID NO:40) hybridization probe 1 : 5'-TGATCGCGATGGGGACAAAGGCGCAAGCTCGAGAGGAAACTGTTGTGCCT-3' (SEQ ID NO-41)
  • DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO301 gene using the probe oligonucleotide and one of the PCR primers.
  • RNA for construction of the cDNA libraries was isolated from human fetal kidney tissue. DNA sequencing of the isolated clones isolated as described above gave the full-length DNA sequence for DNA40628-1216 [ Figure 15, SEQ ID NO:34]; and the derived protein sequence for PRO301.
  • DNA40628-1216 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 52-54, and an apparent stop codon at nucleotide positions 949-951.
  • the predicted polypeptide precursor is 299 amino acids long.
  • Analysis of the full-length PRO301 sequence shown in Figure 16 (SEQ ID NO:35) evidences the presence of a variety of important polypeptide domains, wherein the locations given for those important polypeptide domains are approximate as described above.
  • a signal peptide from about amino acid 1 to about amino acid 27; a transmembrane domain from about amino acid 235 to about amino acid 256; an N- glycosylation site from about amino acid 185 to about amino acid 189; a cAMP- and cGMP-dependent protein kinase phosphorylation site from about amino acid 270 to about amino acid 274; and N-myristoylation sites from about amino acid 105 to about amino acid 1 1 1 , from about amino acid 1 16 to about amino acid 122, from about amino acid 158 to about amino acid 164, from about amino acid 219 to about amino acid 225, from about amino acid 237 to about amino acid 243, and from about amino acid 256 to about amino acid 262.
  • PRO301 shows amino acid sequence identity to the A33 antigen precursor (30%) and the coxsackie and adenovirus receptor protein (29%).
  • EXAMPLE 10 Isolation of cDNA clones Encoding Human PRQ526 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. An initial consensus sequence was identified designated herein as DNA39626.init. In addition, the initial consensus DNA sequence was extended using repeated cycles of BLAST and phrap to extend the initial consensus sequence as far as possible using the sources of EST sequences discussed above. The assembled consensus sequence is designated herein as ⁇ consen01 >.
  • oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PR0526.
  • a pair of PCR primers (forward and reverse) were synthesized: forward PCR primer:
  • hybridization probe 5'-AGGCACTGCCTGATGACACCTTCCGCGACCTGGGCAACCTCACAC-3' (SEQ ID NO:46)
  • RNA for construction of the cDNA libraries was isolated from human fetal liver tissue (LIB228).
  • DNA sequencing of the isolated clones isolated as described above gave the full-length DNA sequence for DNA44184-1319 [Figure 17, SEQ ID NO:42]; and the derived protein sequence for PR0526.
  • the entire coding sequence of DNA44184- 1319 is included in Figure 17 (SEQ ID NO:42).
  • Clone DNA44184-1319 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 514-516, and an apparent stop codon at nucleotide positions 1933-1935.
  • the predicted polypeptide precursor is 473 amino acids long.
  • Analysis of the full-length PR0526 sequence shown in Figure 18 evidences the presence of a variety of important polypeptide domains, wherein the locations given for those important polypeptide domains are approximate as described above.
  • a signal peptide from about amino acid 1 to about amino acid 26; a leucine zipper pattern from about amino acid 135 to about amino acid 157; a glycosaminoglycan attachment site from about amino acid 436 to about amino acid 440; N-glycosylation sites from about amino acid 82 to about amino acid 86, from about amino acid 179 to about amino acid 183, from about amino acid 237 to about amino acid 241, from about amino acid 372 to about amino acid 376, and from about amino acid 423 to about amino acid 427; and a von Willebrand factor (VWF) type C domain from about amino acid 41 1 to about amino acid 427.
  • VWF von Willebrand factor
  • PR0526 is a novel protein which is involved in protein-protein interactions.
  • DNA42257 consensus sequence oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for
  • forward PCR primer 1 A pair of PCR primers (forward and reverse) were synthesized: forward PCR primer 1 :
  • RNA for construction of the cDNA libraries was isolated from human fetal brain tissue (LIB153).
  • DNA sequencing of the isolated clones isolated as described above gave the full-length DNA sequence for DNA45416-1251 [ Figure 19, SEQ ID NO:47]; and the derived protein sequence for PR0362.
  • DNA45416-1251 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 1 19-121, and an apparent stop codon at nucleotide positions 1082-1084.
  • the predicted polypeptide precursor is 321 amino acids long.
  • Analysis of the full-length PR0362 sequence shown in Figure 20 evidences the presence of a variety of important polypeptide domains, wherein the locations given for those important polypeptide domains are approximate as described above.
  • a signal peptide from about amino acid 1 to about amino acid 19; a transmembrane domain from about amino acid 281 to about amino acid 300; a glycosaminoglycan attachment site from about amino acid 149 to about amino acid 153; a cAMP- and cGMP-dependent protein kinase phosphorylation site from about amino acid 308 to about amino acid 312; and N- myristoylation sites from about amino acid 2 to about amino acid 8, from about amino acid 148 to about amino acid 154, from about amino acid 158 to about amino acid 164, from about amino acid 207 to about amino acid 213, and from about amino acid 215 to about amino acid 221.
  • Clone DN A45416-1251 has been deposited with the ATCC on February 5, 1998 and is assigned ATCC deposit no.209620.
  • the full-length PR0362 protein shown in Figure 20 has an estimated molecular weight of about 35,544 daltons and a pi of about 8.51.
  • EXAMPLE 12 Isolation of cDNA clones Encoding Human PRQ356
  • An expressed sequence tag (EST) DNA database (LIFESEQ®, Incyte Pharmaceuticals, Palo Alto, CA) was searched and an EST (#2939340) was identified that had homology to PRO 179 [identified in EXAMPLE 2 above and designated DNA 16451-1078 ( Figure l ; SEQ IDNO:l)].
  • EST expressed sequence tag
  • the cDNA libraries used to isolate the cDNA clones encoding human PR0356 were constructed by standard methods using commercially available reagents such as those from Invitrogen, San Diego, CA.
  • the cDNA was primed with oligo dT containing a Notl site, linked with blunt to Sail hemikinased adaptors, cleaved with Notl, sized appropriately by gel electrophoresis, and cloned in a defined orientation into a suitable cloning vector (such as pRKB or pRKD; pRK5B is a precursor of pRK5D that does not contain the Sfil site; see, Holmes etal, Science. 253 : 1278- 1280 ( 1991 )) in the unique Xhol and Notl.
  • a suitable cloning vector such as pRKB or pRKD; pRK5B is a precursor of pRK5D that does not contain the Sfil site; see, Holmes
  • Oligonucleotide probes based upon the above described EST sequence were then synthesized: 1 ) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PR0356.
  • Forward and reverse PCR primers generally range from 20-30 nucleotides and are often designed to give a PCR product of about 100-1000 bp in length.
  • the probe sequences are typically 40-55 bp in length.
  • DNA from the libraries was screened by PCR amplification, as per Ausubel et al, Current Protocols in Molecular Biology, supra, with the PCR primer pair. A positive library was then used to isolate clones encoding the gene of interest using the probe oligonucleotide and one of the primer pairs.
  • the oligonucleotide sequences used were as follows:
  • a cDNA clone was identified and sequenced in entirety.
  • the entire nucleotide sequence of DNA47470-1 130-P1 is shown in Figure 21 (SEQ ID NO:54).
  • Clone DNA47470-1 130-P1 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 215-217, and a stop codon at nucleotide positions 1253-1255 ( Figure 21; SEQ ID NO:54).
  • the predicted polypeptide precursor is 346 amino acids long, and has a calculated molecular weight of approximately 40,018 daltons and an estimated pi of about 8.19.
  • the full-length PR0356 protein is shown in Figure 22 (SEQ ID NO:55).
  • a bacteriophage library of human retinal cDNA (commercially available from Clontech) was screened by hybridization with a synthetic oligonucleotide probe based on an EST sequence (GenBank locus AA021617), which showed some degree of homology to members of the TNFR family.
  • the oligonucleotide probe employed in the screening was 60 bp long. Five positive clones (containing cDNA inserts of 1.8-1.9 kb) were identified in the cDNA library, and the positive clones were confirmed to be specific by PCR using the above hybridization probe as a PCR primer.
  • Single phage plaques containing each of the five positive clones were isolated by limiting dilution and the DNA was purified using a Wizard Lambda Prep DNA purification kit (commercially available from Promega).
  • the cDNA inserts from three of the five bacteriophage clones were excised from the vector arms by digestion with EcoRI, gel-purified, and subcloned into pRK5 and sequenced on both strands.
  • the three clones contained an identical open reading frame (with the exception of an intron found in one of the clones).
  • the entire nucleotide sequence of DNA50148- 1068 is shown in Figure 23 (SEQ ID NO: 59).
  • the cDNA contained one open reading frame with a translational initiation site assigned to the ATG codon at nucleotide positions 82-84.
  • the open reading frame ends at the termination codon TGA at nucleotide positions 931-933.
  • the predicted amino acid sequence of the full length PRO509 polypeptide sequence contains 283 amino acids.
  • the full-length PRO509 protein is shown in Figure 24 (SEQ ID NO:60) and has an estimated molecular weight of approximately 30,420 and a pi of about 7.34.
  • EXAMPLE 14 Isolation of cDNA clones Encoding Human PRQ866 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is designated herein as DNA42257. Based on the DNA44708 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PR0866.
  • forward PCR primer 1 5'-CAGCACTGCCAGGGGAAGAGGG-3' (SEQ ID NO:63)
  • forward PCR primer 2 5'-CAGCACTGCCAGGGGAAGAGGG-3' (SEQ ID NO:63)
  • hybridization probe 5'-CAGCCCCTTCTCCTCCTTTCTCCCACGTCCTATCTGCCTCTC-3' (SEQ ID NO:69)
  • RNA for construction of the cDNA libraries was isolated from human fetal kidney tissue (LIB228).
  • DNA sequencing of the isolated clones isolated as described above gave the full-length DNA sequence for DNA53971-1359 [ Figure 25, SEQ ID NO:61 ]; and the derived protein sequence for PR0866.
  • a signal peptide from about amino acid 1 to about amino acid 26; a glycosaminoglycan attachment site from about amino acid 131 to about amino acid 135; a cAMP- and cGMP-dependent protein kinase phosphorylation site from about amino acid 144 to about amino acid 148; and N-myristoylation sites from about amino acid 26 to about amino acid 32, from about amino acid 74 to about amino acid 80, from about amino acid 132 to about amino acid 138, from about amino acid 134 to about amino acid 140, from about amino acid 190 to about amino acid 196, from about amino acid 287 to about amino acid 293, and from about amino acid 290 to about amino acid 296.
  • Clone DNA53971 -1359 has been deposited with the ATCC on April 4, 1998 and is assigned ATCC deposit no. 209750.
  • the full-length PR0866 protein shown in Figure 26 has an estimated molecular weight of about 35,844 daltons and a pi of about 5.45.
  • In situ Hybridization is a powerful and versatile technique forthe detection and localization of nucleic acid sequences within cell or tissue preparations. It may be useful, for example, to identify sites of gene expression, analyze the tissue distribution of transcription, identify and localize viral infection, follow changes in specific mRNA synthesis, and aid in chromosome mapping.
  • In situ hybridization was performed following an optimized version of the protocol by Lu and Gillett, Cell Vision. 1: 169-176 (1994), using PCR-generated 33 P-labeled riboprobes. Briefly, formalin-fixed, paraffin- embedded human tissues were sectioned, deparaffinized, deproteinated in proteinase K (20 g/ml) for 15 minutes at 37 °C, and further processed for in situ hybridization as described by Lu and Gillett, supra. A ( 33 -P)UTP-labeled antisense riboprobe was generated from a PCR product and hybridized at 55 °C overnight. The slides were dipped in Kodak NTB2TM nuclear track emulsion and exposed for 4 weeks. 33 P-Riboprobe synthesis
  • the tubes were incubated at 37°C for one hour.
  • a total of 1.0 ⁇ l RQ1 DNase was added, followed by incubation at 37°C for 15 minutes.
  • a total of 90 ⁇ l TE (10 mM Tris pH 7.6/1 mM EDTA pH 8.0) was added, and the mixture was pipetted onto DE81 paper.
  • the remaining solution was loaded in a MICROCON-50 TM ultrafiltration unit, and spun using program 10 (6 minutes).
  • the filtration unit was inverted over a second tube and spun using program 2 (3 minutes). After the final recovery spin, a total of 100 ⁇ l TE was added, then 1 ⁇ l of the final product was pipetted on DE81 paper and counted in 6 ml of BIOFLUOR IITM.
  • the probe was run on a TBE/urea gel. A total of 1-3 ⁇ l of the probe or 5 ⁇ l of RNA Mrk III was added to 3 ⁇ l of loading buffer. After heating on a 95 °C heat block for three minutes, the gel was immediately placed on ice. The wells of gel were flushed, and the sample was loaded and run at 180-250 volts for 45 minutes. The gel was wrapped in plastic wrap (SARANTM brand) and exposed to XAR film with an intensifying screen in a - 70 °C freezer one hour to overnight.
  • SARANTM brand plastic wrap
  • the slides were removed from the freezer, placed on aluminum trays, and thawed at room temperature for 5 minutes. The trays were placed in a 55 °C incubator for five minutes to reduce condensation. The slides were fixed for 10 minutes in 4% paraformaldehyde on ice in the fume hood, and washed in 0.5 x SSC for 5 minutes, at room temperature (25 ml 20 x SSC + 975 ml SQ H 2 0). After deproteination in 0.5 ⁇ g/ml proteinase K for 10 minutes at 37°C (12.5 ⁇ l of 10 mg/ml stock in 250 ml prewarmed RNAse-free RNAse buffer), the sections were washed in 0.5 x SSC for 10 minutes at room temperature. The sections were dehydrated in 70%, 95%, and 100% ethanol, 2 minutes each. B. Pretreatment of paraffin-embedded sections
  • the slides were deparaffinized, placed in SQ H,0, and rinsed twice in 2 x SSC at room temperature, for
  • the slides were laid out in a plastic box lined with Box buffer (4 x SSC, 50% formamide) - saturated filter paper
  • the tissue was covered with 50 ⁇ l of hybridization buffer (3 75 g dextran sulfate + 6 ml SQ H,0), vortexed, and heated in the microwave for 2 minutes with the cap loosened After cooling on ice, 18 75 ml formamide, 3 75 ml 20 x SSC, and 9 ml SQ H 2 0 were added, and the tissue was vortexed well and incubated at 42 °C for 1-4 hours
  • DNA40628-1216 (PRO301 ) pi 5'-CTATGAAATTAACCCTCACTAAAGGGACAGACGGGGCAGCAGGGAGTG-3'(SEQIDNO 75) (5) DNA40628-1216 (PRO301 ) pi :
  • DNA30879-1 152 (PRO207) (Apo2L Homolog) Low-level expression was observed over a chondrosarcoma, and over one other soft-tissue sarcoma. All other tissues were negative.
  • Human fetal tissues examined included: placenta,umbilical cord, liver, kidney, adrenals, thyroid, lungs, heart, great vessels, esophagus, stomach, small intestine, spleen, thymus, pancreas, brain, eye, spinal cord, body wall, pelvis and lower limb.
  • Adult tissues examined included: kidney (normal and end-stage), adrenal, myocardium, spleen, lymph node, pancreas, lung, skin, eye (including retina), bladder, and liver (normal, cirrhotic, acute failure).
  • Non-human primate tissues examined included:
  • Chimp tissues salivary gland, stomach, thyroid, parathyroid, tongue, thymus, ovary, and lymph node.
  • Rhesus monkey tissues cerebral cortex, hippocampus, cerebellum, penis
  • DNA33221 -1 133 (PRQ224) (LDLR homolog - 1 TM) Observed expression was limited to vascular endothelium in fetal spleen, adult spleen, fetal liver, adult thyroid and adult lymph node (chimp). Additional site of expression was seen in the developing spinal ganglia. All other tissues were negative.
  • Human fetal tissues examined included: placenta, umbilical cord, liver, kidney, adrenals, thyroid, lungs, heart, great vessels, esophagus, stomach, small intestine, spleen, thymus, pancreas, brain, eye, spinal cord, body wall, pelvis and lower limb.
  • Chimp tissues salivary gland, stomach, thyroid, parathyroid, skin, thymus, ovary, lymph node.
  • Rhesus monkey tissues cerebral cortex, hippocampus, cerebellum, penis.
  • DNA40628-1216 (PRO301 UCD22 homolog (JAM hlog, A33 Ag hlog)
  • inflamed human tissues psoriasis, 1BD, inflamed kidney, inflamed lung, hepatitis, normal tonsil, adult and chimp multiblocks
  • Expression was evaluated in predominantly inflamed human tissue with a few normal human and non- human primate tissues. Expression was seen in every epithelial structure evaluated including the mucosal epithelium of the colon, bronchial large airway epithelium, oral mucosa (tongue), tonsillar crypt mucosa, placental mucosa, prostatic mucosa, glandular stomach mucosa, epithelial cells of thymic Hassall's corpuscles, hepatocytes, biliary epithelium, and placental epithelium. The only evidence of expression outside of an epithelial structure was weak low, inconsistent expression in the germinal centers of follicles in a tonsil with reactive hyperplasia. In non-human primate tissues the following was observed:
  • Chimp tissues weak diffuse expression was observed in the epidermis of the tongue epithelium; in the thymus, weak specific expression was seen in thymic epithelium of Hassall's corpuscles; in the stomach, mild diffuse expression was observed in the epithelium of the glandular mucosa.
  • liver multiblock including: chronic cholangitis, lobular hyperplasia, acetominophen toxicity: there was diffuse low to moderate expression in hepatocytes and biliary epithelium.
  • Expression was most prominent in perilobular/periportal hepatocytes. It was most prominent in biliary eptithelium in sections of the liver with chronic sclerosing cholangitis. Expression was not present in all samples present; this may reflect sample quality more than expression variability.
  • This novel protein was evaluated in a variety of human and non-human primate tissues and was found to be highly restricted. Expression was present only in alveolar macrophages in the lung and Kupffer cells of the hepatic sinusoids. Expression in these cells was significantly increased when these distinct cell populations were activated. Although these two subpopulations of tissue macrophages are located in different organs, they have similar biological functions. Both types of these phagocytes act as biological filters to remove material from the blood stream or airways including pathogens, senescent cells and proteins and both are capable of secreting a wide variety of important proinflammatory cytokines.
  • inflamed lung (seven patient samples), expression was prominent in reactive alveolar macrophage cell populations defined as large, pale often vacuolated cells present singly or in aggregates within alveoli and was weak to negative in normal, non-reactive macrophages (single scattered cells of normal size). Expression in alveolar macrophages was increased during inflammation when these cells were both increased in numbers and size (activated). Despite the presence of histocytes in areas of interstitial inflammation and peribronchial lymphoid hyperplasia in these tissues, expression was restricted to alveolar macrophages. Many of the inflamed lungs also had some degree of suppurative inflammation; expression was not present in neutrophilic granulocytes.
  • PRQ356, PRO509 or PRQ866 as a Hybridization Probe
  • the following method describes use of a nucleotide sequence encoding PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 as a hybridization probe.
  • DNA comprising the coding sequence of full-length or mature PRO 179, PRO207, PRO320, PR0219,
  • PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 (as shown in Figure 1, 3, 5, 7, 9, 1 1, 13, 15, 17, 19, 21 , 23, and 25, respectively, SEQ ID NOS: 1, 6, 9, 14, 19, 24, 29, 34, 42, 47, 54, 59, and 61 , respectively) or a fragment thereof is employed as a probe to screen for homologous DNAs (such as those encoding naturally-occurring variants of PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866) in human tissue cDNA libraries or human tissue genomic libraries.
  • homologous DNAs such as those encoding naturally-occurring variants of PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866
  • Hybridization and washing of filters containing either library DNAs is performed under the following high-stringency conditions.
  • Hybridization of radiolabeled probe derived from the gene encoding a PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide to the filters is performed in a solution of 50% formamide, 5x SSC, 0.1% SDS, 0.1% sodium pyrophosphate, 50 mM sodium phosphate, pH 6.8, 2x Denhardt's solution, and 10% dextran sulfate at 42°C for 20 hours. Washing of the filters is performed in an aqueous solution of 0.1 x SSC and 0.1% SDS at 42°C.
  • DNAs having a desired sequence identity with the DNA encoding full-length native sequence can then be identified using standard techniques known in the art.
  • PRO207. PRO320. PRQ219. PRQ221. PRQ224. PRQ328. PRO301. PRQ526. PRQ362. PRQ356. PRO509 or PRQ866 in E. coli This example illustrates preparation of an unglycosylated form of PROl 79, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 by recombinant expression in E. coli.
  • the DNA sequence encoding PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 is initially amplified using selected PCR primers.
  • the primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector.
  • a variety of expression vectors may be employed.
  • An example of a suitable vector is pBR322 (derived from E. coli; see Bolivar et al, Gene, 2:95 (1977)) which contains genes for ampicillin and tetracycline resistance.
  • the vector is digested with restriction enzyme and dephosphorylated.
  • the PCR amplified sequences are then ligated into the vector.
  • the vector will preferably include sequences which encode for an antibiotic resistance gene, a tip promoter, a poly-His leader (including the first six STII codons, poly-His sequence, and enterokinase cleavage site), the PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 coding region, lambda transcriptional terminator, and an argU gene.
  • the ligation mixture is then used to transform a selected E. coli strain using the methods described in Sambrook et al, supra. Transformants are identified by their ability to grow on LB plates and antibiotic resistant colonies are then selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing.
  • Selected clones can be grown overnight in liquid culture medium such as LB broth supplemented with antibiotics.
  • the overnight culture may subsequently be used to inoculate a larger scale culture.
  • the cells are then grown to a desired optical density, during which the expression promoter is turned on.
  • the cells After culturing the cells for several more hours, the cells can be harvested by centrifugation.
  • the cell pellet obtained by the centrifugation can be solubilized using various agents known in the art, and the solubilized PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 protein can then be purified using a metal chelating column under conditions that allow tight binding of the protein.
  • PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 may be expressed in E. coli in a poly-His tagged form, using the following procedure.
  • the DNA encoding PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 is initially amplified using selected PCR primers.
  • the primers will contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector, and other useful sequences providing for efficient and reliable translation initiation, rapid purification on a metal chelation column, and proteolytic removal with enterokinase.
  • the PCR-amplified, poly-His tagged sequences are then ligated into an expression vector, which is used to transform an E. coli host based on strain 52 (W31 10 fuhA(tonA) Ion galE rpoHts(htpRts) clpP(ladq). Transformants are first grown in LB containing 50 mg/ml carbenicillin at 30°C with shaking until an OD 600 of 3-5 is reached.
  • Cultures are then diluted 50-100 fold into CRAP media (prepared by mixing 3.57 g (NH 4 ) 2 S0 4 , 0.71 g sodium citrate « 2H20, 1.07 g KCI, 5.36 g Difco yeast extract, 5.36 g Sheffield hycase SF in 500 ml water, as well as 110 mM MPOS, pH 7.3, 0.55% (w/v) glucose and 7 mM MgS0 4 ) and grown for approximately 20-30 hours at 30 °C with shaking. Samples are removed to verify expression by SDS-PAGE analysis, and the bulk culture is centrifuged to pellet the cells. Cell pellets are frozen until purification and refolding.
  • CRAP media prepared by mixing 3.57 g (NH 4 ) 2 S0 4 , 0.71 g sodium citrate « 2H20, 1.07 g KCI, 5.36 g Difco yeast extract, 5.36 g Sheffield hycase SF in 500 ml water, as well as 110 mM MPOS
  • E. coli paste from 0.5 to 1 L fermentations (6-10 g pellets) is resuspended in 10 volumes (w/v) in 7 M guanidine, 20 mM Tris, pH 8 buffer.
  • Solid sodium sulfite and sodium tetrathionate is added to make final concentrations of 0.1 M and 0.02 M, respectively, and the solution is stirred overnight at 4 C C. This step results in a denatured protein with all cysteine residues blocked by sulfitolization.
  • the solution is centrifuged at 40,000 rpm in a Beckman Ultracentifuge for 30 min.
  • the supernatant is diluted with 3-5 volumes of metal chelate column buffer (6 M guanidine, 20 mM Tris, pH 7.4) and filtered through 0.22 micron filters to clarify.
  • the clarified extract is loaded onto a 5 ml Qiagen Ni 2+ -NTA metal chelate column equilibrated in the metal chelate column buffer.
  • the column is washed with additional buffer containing 50 mM imidazole (Calbiochem, Utrol grade), pH 7.4.
  • the protein is eluted with buffer containing 250 mM imidazole. Fractions containing the desired protein are pooled and stored at 4°C. Protein concentration is estimated by its absorbance at 280 nm using the calculated extinction coefficient based on its amino acid sequence.
  • the proteins are refolded by diluting the sample slowly into freshly prepared refolding buffer consisting of: 20 mM Tris, pH 8.6, 0.3 M NaCl, 2.5 M urea, 5 mM cysteine, 20 mM glycine and 1 mM EDTA. Refolding volumes are chosen so that the final protein concentration is between 50 to 100 micrograms/ml.
  • the refolding solution is stirred gently at 4°C for 12-36 hours.
  • the refolding reaction is quenched by the addition of TFA to a final concentration of 0.4% (pH of approximately 3).
  • the solution is filtered through a 0.22 micron filter and acetonitrile is added to 2- 10% final concentration.
  • the refolded protein is chromatographed on a Poros Rl/H reversed phase column using a mobile buffer of 0.1% TFA with elution with a gradient of acetonitrile from 10 to 80%. Aliquots of fractions with A 280 absorbance are analyzed on SDS polyacrylamide gels and fractions containing homogeneous refolded protein are pooled. Generally, the properly refolded species of most proteins are eluted at the lowest concentrations of acetonitrile since those species are the most compact with their hydrophobic interiors shielded from interaction with the reversed phase resin. Aggregated species are usually eluted at higher acetonitrile concentrations. In addition to resolving misfolded forms of proteins from the desired form, the reversed phase step also removes endotoxin from the samples.
  • Fractions containing the desired folded PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 polypeptide are pooled and the acetonitrile removed using a gentle stream of nitrogen directed at the solution. Proteins are formulated into 20 mM Hepes, pH 6.8 with 0.14 M sodium chloride and 4% mannitol by dialysis or by gel filtration using G25 Superfine (Pharmacia) resins equilibrated in the formulation buffer and sterile filtered.
  • PRO207, PR0224, and PRO301 were successfully expressed in E. coli in a poly-His tagged form by the above procedure.
  • This example illustrates preparation of a potentially glycosylated form of PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PRO356,PRO509 or PRO866 by recombinant expression in mammalian cells.
  • the vector, pRK5 (see EP 307,247, published March 15, 1989), is employed as the expression vector.
  • the PROl 79, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 DNA is ligated into pRK5 with selected restriction enzymes to allow insertion of the PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 DNA using ligation methods such as described in Sambrook etal, supra.
  • the resulting vector is called pRK5-PRO 179,pRK5-PRO207,pRK5-PRO320,pRK5-PRO219,pRK5-PR0221 ,pRK5-PR0224, pRK5- PR0328, pRK5-PRO301, pRK5-PR0526, pRK5-PR0362, pRK5-PR0356, pRK5-PRO509 or pRK5-PR0866, respectively.
  • the selected host cells may be 293 cells.
  • Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components and/or antibiotics.
  • pRK5-PRO 179, pRK5-PRO207, pRK5-PRO320, pRK5-PRO219,pRK5-PRO221 ,pRK5-PRO224,pRK5-PRO328,pRK5-PRO301,pRK5-PRO526,pRK5-PRO362, pRK5-PR0356, pRK5-PRO509 or pRK5-PR0866 DNA is mixed with about 1 ⁇ g DNA encoding the VA RNA gene [Thimmappaya et al, Cell, 31:543 (1982)] and dissolved in 500 ⁇ l of 1 mM Tris-HCI, 0.1 mM EDTA, 0.227 M CaCl 2 .
  • the culture medium is removed and replaced with culture medium (alone) or culture medium containing 200 ⁇ Ci/ l 35 S-cysteine and 200 ⁇ Ci/ml 35 S-methionine.
  • the conditioned medium is collected, concentrated on a spin filter, and loaded onto a 15% SDS gel.
  • the processed gel may be dried and exposed to film for a selected period of time to reveal the presence of the PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide.
  • the cultures containing transfected cells may undergo further incubation (in serum free medium) and the medium is tested in selected bioassays.
  • PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 may be introduced into 293 cells transiently using the dextran sulfate method described by Somparyrac et al, Proc. Natl. Acad. Sci.. 12:7575 (1981).
  • 293 cells are grown to maximal density in a spinner flask and 700 ⁇ g pRK5-PR0179, pRK5-PRO207, pRK5-PRO320, pRK5-PR0219, pRK5-PRO221,pRK5-PRO224,pRK5-PRO328,pRK5-PRO301 ,pRK5-PRO526,pRK5-PRO362,pRK5-PRO356, pRK5-PRO509 or pRK5-PR0866 DNA is added.
  • the cells are first concentrated from the spinner flask by centrifugation and washed with PBS. The DNA-dextran precipitate is incubated on the cell pellet for four hours.
  • the cells are treated with 20% glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, 5 ⁇ g/ml bovine insulin and 0.1 ⁇ g/ml bovine transferrin. After about four days, the conditioned media is centrifuged and filtered to remove cells and debris.
  • the sample containing expressed PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 can then be concentrated and purified by any selected method, such as dialysis and/or column chromatography. In another embodiment, PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 ,
  • PR0526, PR0362, PR0356, PRO509 or PR0866 can be expressed in CHO cells.
  • the pRK5-PR0179, pRK5- PRO207, pRK5-PRO320, pRK5-PR0219, pRK5-PR0221, pRK5-PR0224, pRK5-PR0328, pRK5-PRO301 , pRK5-PR0526, pRK5-PR0362, pRK5-PR0356, pRK5-PRO509 orpRK5-PR0866 can be transfected into CHO cells using known reagents such as CaP0 4 or DEAE-dextran.
  • the cell cultures can be incubated, and the medium replaced with culture medium (alone) or medium containing a radiolabel such as 35 S- methionine.
  • culture medium alone
  • medium containing a radiolabel such as 35 S- methionine.
  • the culture medium may be replaced with serum free medium.
  • the cultures are incubated for about 6 days, and then the conditioned medium is harvested.
  • the medium containing the expressed PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 polypeptide can then be concentrated and purified by any selected method.
  • Epitope-tagged PR0179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 may also be expressed in host CHO cells.
  • the PR0179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 may be subcloned out of the pRK5 vector.
  • the subclone insert can undergo PCR to fuse in frame with a selected epitope tag such as a poly-His tag into a Baculovirus expression vector.
  • the poly-His tagged PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 insert can then be subcloned into a SV40 driven vector containing a selection marker such as DHFR for selection of stable clones.
  • a selection marker such as DHFR for selection of stable clones.
  • the CHO cells can be transfected (as described above) with the SV40 driven vector. Labeling may be performed, as described above, to verify expression.
  • the culture medium containing the expressed poly-His tagged PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 can then be concentrated and purified by any selected method, such as by Ni 2+ -chelate affinity chromatography.
  • PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 may also be expressed in CHO and/or COS cells by a transient expression procedure or in CHO cells by another stable expression procedure.
  • Stable expression in CHO cells is performed using the following procedure.
  • the proteins are expressed as an IgG construct (immunoadhesin), in which the coding sequences for the soluble forms (e.g., extracellular domains) of the respective proteins are fused to an IgGl constant region sequence containing the hinge, CH2 and CH2 domains and/or as a poly-His tagged form.
  • CHO expression vectors are constructed to have compatible restriction sites 5' and 3' of the DNA of interest to allow the convenient shuttling of cDNA's.
  • the vector used in expression in CHO cells is as described in Lucas et al, Nucl. Acids Res.. 24:9 (1774-1779 (1996), and uses the SV40 early promoter/enhancer to drive expression of the cDNA of interest and dihydrofolate reductase (DHFR).
  • DHFR expression permits selection for stable maintenance of the plasmid following transfection.
  • Twelve micrograms of the desired plasmid DNA is introduced into approximately 10 million CHO cells using commercially available transfection reagents Superfect ® (Quiagen), Dosper ® or Fugene ® (Boehringer Mannheim). The cells are grown as described in Lucas et al. , supra. Approximately 3 x 10 "7 cells are frozen in an ampule for further growth and production as described below. The ampules containing the plasmid DNA are thawed by placement into a water bath and mixed by vortexing. The contents are pipetted into a centrifuge tube containing 10 mis of media and centrifuged at 1000 rpm for 5 minutes.
  • the supernatant is aspirated and the cells are resuspended in 10 ml of selective media (0.2 ⁇ m filtered PS20 with 5% 0.2 ⁇ m diafiltered fetal bovine serum).
  • the cells are then aliquoted into a 100 ml spinner containing 90 ml of selective media. After 1-2 days, the cells are transferred into a 250 ml spinner filled with 150 ml selective growth medium and incubated at 37°C. After another 2-3 days, 250 ml, 500 ml and 2000 ml spinners are seeded with 3 x 10 5 cells/ml.
  • the cell media is exchanged with fresh media by centrifugation and resuspension in production medium.
  • a 3L production spinner is seeded at 1.2 x 10 6 cells/ml. On day 0, the cell number and pH is determined. On day 1 , the spinner is sampled and sparging with filtered air is commenced. On day 2, the spinner is sampled, the temperature shifted to 33°C, and 30 ml of 500 g/L glucose and 0.6 ml of 10% antifoam (e.g., 35% polydimethylsiloxane emulsion, Dow Corning 365 Medical Grade Emulsion) taken. Throughout the production, the pH is adjusted as necessary to keep it at around 7.2.
  • 10% antifoam e.g., 35% polydimethylsiloxane emulsion, Dow Corning 365 Medical Grade Emulsion
  • the cell culture is harvested by centrifugation and filtering through a 0.22 ⁇ m filter.
  • the filtrate is either stored at 4°C or immediately loaded onto columns for purification.
  • the proteins are purified using a Ni 2+ -NTA column (Qiagen).
  • imidazole is added to the conditioned media to a concentration of 5 mM.
  • the conditioned media is pumped onto a 6 ml Ni 2+ -NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rate of 4-5 ml/min. at 4°C.
  • the column After loading, the column is washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole.
  • the highly purified protein is subsequently desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCl and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80°C.
  • Immunoadhesin (Fc-containing) constructs are purified from the conditioned media as follows.
  • the conditioned medium is pumped onto a 5 ml Protein A column (Pharmacia) which has been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column is washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5.
  • the eluted protein is immediately neutralized by collecting 1 ml fractions into tubes containing 275 ⁇ l of 1 M Tris buffer, pH 9.
  • the highly purified protein is subsequently desalted into storage buffer as described above for the poly-His tagged proteins. The homogeneity is assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation.
  • PRO 179, PRO320, PR0219, PR0221 , PR0224.PR0328, PRO301 , PR0356, PRO509, and PR0866 were stably expressed in CHO cells by the above described method.
  • PR0224, PR0328, PRO301 , and PR0356 were expressed in CHO cells by the transient expression procedure.
  • PRO207 PRO207, PRO320. PRQ219. PRQ221, PRQ224. PRQ328. PRO301 , PRQ526,
  • PRO509 or PRQ866 in Yeast The following method describes recombinant expression of PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 in yeast.
  • yeast expression vectors are constructed for intracellular production or secretion of PROl 79,
  • DNA encoding PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression of PROl 79, PRO207.
  • PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression of PROl 79, PRO207.
  • DNA encoding PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 can be cloned into the selected plasmid, together with DNA encoding the ADH2/GAPDH promoter, a native PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866 signal peptide or other mammalian signal peptide, or, for example, a yeast alpha-factor or invertase secretory signal/leader sequence, and linker sequences (if needed) for expression of PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866.
  • yeast cells such as yeast strain AB110
  • yeast cells can then be transformed with the expression plasmids described above and cultured in selected fermentation media.
  • the transformed yeast supernatants can be analyzed by precipitation with 10% trichloroacedc acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain.
  • Recombinant PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected cartridge filters.
  • the concentrate containing PR0179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 may further be purified using selected column chromatography resins.
  • PRO207. PRO320. PRQ219. PRQ221. PRQ224. PRQ328. PRO301. PRQ526. PRQ362. PRQ356. PRO509 or PRQ866 in Baculovirus-infected Insect Cells The following method describes recombinant expression in Baculovirus-infected insect cells. The sequence coding for PROl 79, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 is fused upstream of an epitope tag contained within a baculovirus expression vector.
  • epitope tags include poly-His tags and immunoglobulin tags (like Fc regions of IgG).
  • a variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pVL1393 (Novagen).
  • the sequence encoding PR0179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 or the desired portion of the coding sequence of PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 (such as the sequence encoding the extracellular domain of a transmembrane protein or the sequence encoding the mature protein if the protein is extracellular) is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is then digested with those selected restriction enzymes and subcloned into the expression vector.
  • Recombinant baculovirus is generated by co-transfecting the above plasmid and BaculoGoldTM virusDNA (Pharmingen) into Spodopterafrugiperda (“Sf9”) cells (ATCC CRL 171 1 )using lipofectin (commercially available from GIBCO-BRL). After4 - 5 days of incubation at 28°C, the released viruses are harvested and used for further amplifications. Viral infection and protein expression are performed as described by O'Reilley et al, Baculovirus expression vectors: A Laboratory Manual, Oxford: Oxford University Press (1994).
  • Expressed poly-His tagged PRO 179,PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PRO866 can then be purified, for example, by Ni + -chelate affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert et al. Nature. 362: 175-179 (1993).
  • Sf9 cells are washed, resuspended in sonication buffer (25 ml Hepes, pH 7.9; 12.5 mM MgCl 2 ; 0.1 mM EDTA; 10% glycerol; 0.1% NP-40; 0.4 M KCI), and sonicated twice for 20 seconds on ice.
  • the sonicates are cleared by centrifugation, and the supernatant is diluted 50-fold in loading buffer (50 mM phosphate, 300 mM NaCl, 10% glycerol, pH 7.8) and filtered through a 0.45 mm filter.
  • a Ni + -NTA agarose column (commercially available from Qiagen) is prepared with a bed volume of 5 ml, washed with 25 ml of water and equilibrated with 25 ml of loading buffer. The filtered cell extract is loaded onto the column at 0.5 ml per minute. The column is washed to baseline A 280 with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer (50 mM phosphate; 300 mM NaCl, 10% glycerol, pH 6.0), which elutes nonspecifically bound protein. After reaching A 280 baseline again, the column is developed with a 0 to 500 mM imidazole gradient in the secondary wash buffer.
  • a secondary wash buffer 50 mM phosphate; 300 mM NaCl, 10% glycerol, pH 6.0
  • PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 can be performed using known chromatography techniques, including for instance, Protein A or protein G column chromatography.
  • the respectivecodingsequences are subcloned into a baculovirus expression vector (pb.PH.IgG for IgG fusions and pb.PH.His.c for poly-His tagged proteins), and the vector and Baculogold® baculovirus DNA (Pharmingen) are co-transfected into 105 Spodoptera frugiperda ("Sf9”) cells (ATCC CRL 171 1), using Lipofectin (Gibco BRL).
  • Sf9 Spodoptera frugiperda
  • pb.PH.IgG and pb.PH.His are modifications ofthe commercially available baculovirus expression vector pVL 1393 (Pharmingen), with modified polylinker regions to include the His or Fc tag sequences.
  • the cells are grown in Hink's TNM-FH medium supplemented with 10% FBS (Hyclone). Cells are incubated for 5 days at 28 °C. The supernatant is harvested and subsequently used for the first viral amplification by infecting Sf9 cells in Hink's TNM-FH medium supplemented with 10% FBS at an approximate multiplicity of infection (MOI) of 10. Cells are incubated for 3 days at 28 °C.
  • MOI multiplicity of infection
  • the supernatant is harvested and the expression of the constructs in the baculovirus expression vector is determined by batch binding of 1 ml of supernatant to 25 ml of Ni 2+ -NTA beads (QIAGEN) for histidine tagged proteins or Protein-A Sepharose CL-4B beads (Pharmacia) for IgG tagged proteins followed by SDS-PAGE analysis comparing to a known concentration of protein standard by Coomassie blue staining.
  • the first viral amplification supernatant is used to infect a spinner culture (500 ml) of Sf9 cells grown in ESF-921 medium (Expression Systems LLC) at an approximate MOI of 0.1. Cells are incubated for 3 days at 28 °C. The supernatant is harvested and filtered. Batch binding and SDS-PAGE analysis is repeated, as necessary, until expression ofthe spinner culture is confirmed.
  • the conditioned medium from the transfected cells (0.5 to 3 L) is harvested by centrifugation to remove the cells and filtered through 0.22 micron filters.
  • the protein construct is purified using a Ni 2+ -NTA column (Qiagen). Before purification, imidazole is added to the conditioned media to a concentration of 5 mM.
  • the conditioned media is pumped onto a 6 ml Ni 2+ -NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rate of 4-5 ml/min. at 4°C.
  • the column After loading, the column is washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole.
  • the highly purified protein is subsequently desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCl and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80°C.
  • Immunoadhesin (Fc containing) constructs of proteins are purified from the conditioned media as follows.
  • the conditioned media is pumped onto a 5 ml Protein A column (Pharmacia) which has been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column is washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5.
  • the eluted protein is immediately neutralized by collecting 1 ml fractions into tubes containing 275 ml of 1 M Tris buffer, pH 9.
  • the highly purified protein is subsequently desalted into storage buffer as described above for the poly-His tagged proteins. The homogeneity ofthe proteins is verified by
  • PRO301, PR0362, PR0356, PRO509 and PR0866 were expressed in baculovirus infected Sf9 insect cells.
  • a modified baculovirus procedure may be used incorporating high-5 cells.
  • the DNA encoding the desired sequence is amplified with suitable systems, such as Pfu (Stratagene), or fused upstream (5'-of) of an epitope tag contained with a baculovirus expression vector.
  • suitable systems such as Pfu (Stratagene)
  • epitope tags include poly- His tags and immunoglobulin tags (like Fc regions of IgG).
  • a variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pIE 1 - 1 (Novagen).
  • the pIE 1 - 1 and pIE 1 -2 vectors are designed for constitutive expression of recombinant proteins from the baculovirus iel promoter in stably- transformed insect cells (1).
  • the plasmids differ only in the orientation ofthe multiple cloning sites and contain all promoter sequences known to be important for iel-mediated gene expression in uninfected insect cells as well as the hr5 enhancer element.
  • pIE 1 - 1 and pIE 1 -2 include the translation initiation site and can be used to produce fusion proteins.
  • the desired sequence or the desired portion ofthe sequence (such as the sequence encoding the extracellular domain of a transmembrane protein) is amplified by PCR with primers complementary to the 5' and 3' regions.
  • the 5' primer may incorporate flanking (selected) restriction enzyme sites.
  • the product is then digested with those selected restriction enzymes and subcloned into the expression vector.
  • derivatives of pIEl-1 can include the Fc region of human IgG (pb.PH.IgG) or an 8 histidine (pb.PH.His) tag downstream (3'-of) the desired sequence.
  • the vector construct is sequenced for confirmation.
  • High-5 cells are grown to a confluency of 50% under the conditions of, 27°C, no CO,, NO pen/strep.
  • 30 ⁇ g of pIE based vector containing the sequence is mixed with 1 ml Ex-Cell medium (Media: Ex-Cell 401 + 1/100 L-Glu JRH Biosciences #14401-78P (note: this media is light sensitive)), and in a separate tube, 100 ⁇ l of CellFectin (CellFECTIN (GibcoBRL # 10362-010) (vortexed to mix)) is mixed with 1 ml of Ex-Cell medium.
  • the two solutions are combined and allowed to incubate at room temperature for 15 minutes.
  • Ex-Cell media 8 ml of Ex-Cell media is added to the 2ml of DNA/CellFECTIN mix and this is layered on high-5 cells that have been washed once with Ex-Cell media. The plate is then incubated in darkness for 1 hour at room temperature. The DNA/CellFECTIN mix is then aspirated, and the cells are washed once with Ex-Cell to remove excess CellFECTIN, 30 ml of fresh Ex-Cell media is added and the cells are incubated for 3 days at 28°C.
  • the supernatant is harvested and the expression ofthe sequence in the baculovirus expression vector is determined by batch binding of 1 ml of supernatent to 25 ml of Ni 2+ -NTA beads (QIAGEN) for histidine tagged proteins or Protein-A Sepharose CL-4B beads (Pharmacia) for IgG tagged proteins followed by SDS-PAGE analysis comparing to a known concentration of protein standard by Coomassie blue staining.
  • the conditioned media from the transfected cells (0.5 to 3 L) is harvested by centrifugation to remove the cells and filtered through 0.22 micron filters.
  • the protein comprising the sequence is purified using a Ni 2+ -NTA column (Qiagen). Before purification, imidazole is added to the conditioned media to a concentration of 5 M. The conditioned media is pumped onto a 6 ml Ni 2+ -NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rate of 4-5 ml/min. at 48°C.
  • the column is washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole.
  • the highly purified protein is then subsequently desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCl and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80°C.
  • Immunoadhesin (Fc containing) constructs of proteins are purified from the conditioned media as follows.
  • the conditioned media is pumped onto a 5 ml Protein A column (Pharmacia) which has been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column is washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5.
  • the eluted protein is immediately neutralized by collecting 1 ml fractions into tubes containing 275 ml of 1 M Tris buffer, pH 9.
  • the highly purified protein is subsequently desalted into storage buffer as described above for the poly-His tagged proteins.
  • the homogeneity ofthe sequence is assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation and other analytical procedures as desired or necessary.
  • PRO 179, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, and PR0356 were expressed using the above baculovirus procedure employing high-5 cells.
  • PRO301. PRQ526. PRQ362. PRQ356. PRO509 or PRQ866 This example illustrates preparation of monoclonal antibodies which can specifically bind PR0179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PRO866. Techniques for producing the monoclonal antibodies are known in the art and are described, for instance, in Goding, supra.
  • Immunogens that may be employed include purified PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 fusion proteins containing PRO 179, PRO207, PRO320, PR0219, PR0221, PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 and cells expressing recombinant PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866 on the cell surface. Selection of the immunogen can be made by the skilled artisan without undue experimentation.
  • mice such as Balb/c are immunized with the PRO 179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301 , PR0526, PR0362, PR0356, PRO509 or PR0866 immunogen emulsified in complete Freund's adjuvant and injected subcutaneously or intraperitoneally in an amount from 1-100 micrograms.
  • the immunogen is emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) and injected into the animal's hind foot pads. The immunized mice are then boosted 10 to 12 days later with additional immunogen emulsified in the selected adjuvant.
  • mice may also be boosted with additional immunization injections.
  • Serum samples may be periodically obtained from the mice by retro-orbital bleeding for testing in ELISA assays to detect anti-PRO 179, anti-PRO207, anti-PRO320, anti-PR0219, anti- PR0221, anti-PR0224, anti-PR0328, anti-PRO301 , anti-PR0526, anti-PR0362, anti-PR0356, anti-PRO509 or anti-PR0866 antibodies.
  • the animals "positive" for antibodies can be injected with a final intravenous injection of PR0179, PRO207, PRO320, PR0219, PR0221 , PR0224, PR0328, PRO301, PR0526, PR0362, PR0356, PRO509 or PR0866.
  • the mice are sacrificed and the spleen cells are harvested.
  • the spleen cells are then fused (using 35% polyethylene glycol) to a selected murine myeloma cell line such as P3X63 AgU.1 , available from ATCC, No. CRL 1597.
EP99960644A 1998-12-22 1999-12-02 Methodes permettant d'inhiber la croissance de cellules neoplasiques Withdrawn EP1141284A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04007617A EP1484338B1 (fr) 1998-12-22 1999-12-02 Méthode et composition pour l'inhibition de la croissance des cellules néoplastiques
EP04007618A EP1466977A1 (fr) 1999-03-08 1999-12-02 Procédés et compositions pour l'inhibition de la croissance de cellules néoplastiques
EP07001711A EP1820859B9 (fr) 1998-12-22 1999-12-02 Procédés et compositions d'inhibition de la croissance de cellules néoplasiques
EP09004092A EP2075335A3 (fr) 1998-12-22 1999-12-02 Procédés et compositions d'inhibition de la croissance de cellules néoplasiques

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US11329698P 1998-12-22 1998-12-22
US113296P 1998-12-22
PCT/US1999/005028 WO1999046281A2 (fr) 1998-03-10 1999-03-08 Nouveaux polypeptides et acides nucleiques les codant
WOPCT/US05/00028 1999-03-08
US13023299P 1999-04-21 1999-04-21
US130232P 1999-04-21
US13144599P 1999-04-28 1999-04-28
US131445P 1999-04-28
US13428799P 1999-05-14 1999-05-14
US134287P 1999-05-14
US14475899P 1999-07-20 1999-07-20
US144758P 1999-07-20
US14569899P 1999-07-26 1999-07-26
US145698P 1999-07-26
WOPCT/US21/00547 1999-09-15
PCT/US1999/021547 WO2000015797A2 (fr) 1998-09-17 1999-09-15 Compositions et methodes de traitement des maladies relatives au syteme immunitaire
WOPCT/US21/00090 1999-09-15
PCT/US1999/021090 WO2000015796A2 (fr) 1998-09-16 1999-09-15 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
PCT/US1999/028565 WO2000037638A2 (fr) 1998-12-22 1999-12-02 Methodes permettant d'inhiber la croissance de cellules neoplasiques

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP04007618A Division EP1466977A1 (fr) 1999-03-08 1999-12-02 Procédés et compositions pour l'inhibition de la croissance de cellules néoplastiques
EP04007617A Division EP1484338B1 (fr) 1998-12-22 1999-12-02 Méthode et composition pour l'inhibition de la croissance des cellules néoplastiques

Publications (1)

Publication Number Publication Date
EP1141284A2 true EP1141284A2 (fr) 2001-10-10

Family

ID=27557838

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99960644A Withdrawn EP1141284A2 (fr) 1998-12-22 1999-12-02 Methodes permettant d'inhiber la croissance de cellules neoplasiques

Country Status (13)

Country Link
EP (1) EP1141284A2 (fr)
JP (5) JP3993746B2 (fr)
KR (1) KR100499600B1 (fr)
AT (2) ATE432987T1 (fr)
AU (1) AU768230B2 (fr)
CA (1) CA2353799A1 (fr)
DE (2) DE69935085T2 (fr)
DK (1) DK1484338T3 (fr)
ES (2) ES2281704T3 (fr)
IL (3) IL143031A0 (fr)
MX (1) MXPA01006330A (fr)
PT (1) PT1484338E (fr)
WO (1) WO2000037638A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6808890B2 (en) 1999-07-28 2004-10-26 Nuvelo, Inc. Method of detecting a cancerous cell expressing EGFL6, and EGF mutif protein
US6392019B1 (en) 1997-11-22 2002-05-21 John Ford Antibodies specific for EGF motif proteins
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
CA2309897A1 (fr) 1997-11-22 1999-06-03 Hyseq, Inc. Nouvelle proteine a motifs structuraux du facteur de croissance epidermique obtenue dans une genotheque d'adnc de foie et de rate foetaux
EP1251139A3 (fr) * 1998-04-08 2002-12-18 Genentech, Inc. Protéine semblable à mendin humain et acides nucléiques le codant
AU4682999A (en) 1998-06-16 2000-01-05 Human Genome Sciences, Inc. 94 human secreted proteins
US6960433B1 (en) 1998-10-19 2005-11-01 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
MXPA01007163A (es) 1999-01-15 2002-03-27 Biogen Inc Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
EP1159419A1 (fr) * 1999-03-08 2001-12-05 Genentech, Inc. Activation et inhibition de l'angiogenese et de la cardiovascularisation
JP2003505350A (ja) * 1999-07-20 2003-02-12 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
CN1433482A (zh) * 1999-12-09 2003-07-30 三共株式会社 高脂血症的治疗或预防剂的检验方法
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
YU53502A (sh) * 2000-01-12 2005-11-28 Yale University Blokada aksonalnog rasta posredstvom nogo receptora
CA2408228A1 (fr) 2000-05-08 2001-11-15 Biogen, Inc. Procede servant a favoriser la neovascularisation
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
ATE458815T1 (de) 2000-10-06 2010-03-15 Univ Yale Homologe des nogo rezeptors
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
SI1997512T1 (sl) 2002-04-09 2014-03-31 Biogen Idec Ma Inc. Postopki za zdravljenje stanj, povezanih s TWEAK-om
CA2391438A1 (fr) * 2002-05-01 2003-11-01 Procyon Biopharma Inc. Reactifs et methodes diagnostiques a base de psp94
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
AU2006244014B2 (en) 2005-05-10 2011-03-17 Biogen Ma Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (fr) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Procedes d'evaluation de patients
US7893032B2 (en) 2005-07-07 2011-02-22 Yale University NgR variants and compositions thereof for suppressing axonal growth inhibition
MY151064A (en) 2005-11-04 2014-03-31 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
US8524454B2 (en) 2006-04-07 2013-09-03 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US7776573B2 (en) 2006-06-01 2010-08-17 Genentech, Inc. Crystal structure of CRIg and C3b:CRIg complex
TWI472535B (zh) 2006-11-02 2015-02-11 Genentech Inc 人類化之抗-因子ｄ抗體及其用途
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US9234024B2 (en) 2008-05-06 2016-01-12 Genentech, Inc. Affinity matured CRIg variants
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
EP3368090A1 (fr) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Conjugués de variants d'anticorps anti-facteur d et leurs utilisations
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
CN114835774B (zh) * 2022-06-29 2022-09-27 中国农业大学 辣椒籽分离的寡肽msl及其在预防或治疗癌症中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US5416192A (en) * 1990-04-03 1995-05-16 Bristol-Myers Squibb Company Epithelins: novel cysteine-rich growth modulating proteins
US5028099A (en) * 1990-08-08 1991-07-02 Bertucco Leonard J Trash recycling container
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
AU3661199A (en) * 1998-04-27 1999-11-16 Zymogenetics Inc. Novel polypeptide growth factors and materials and methods for making them
SV1999000069A (es) * 1998-06-02 2000-04-11 Lilly Co Eli Angiopoyetina relacionada con secuencia del gen 3 en la cicatrizacion de la cara ref. x-12261
JP7039446B2 (ja) * 2018-11-29 2022-03-22 株式会社東芝 電子装置

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0037638A2 *

Also Published As

Publication number Publication date
CA2353799A1 (fr) 2000-06-29
IL143031A0 (en) 2002-04-21
IL186154A0 (en) 2008-01-20
WO2000037638A2 (fr) 2000-06-29
ES2327785T3 (es) 2009-11-03
AU1749900A (en) 2000-07-12
JP4037876B2 (ja) 2008-01-23
ATE353339T1 (de) 2007-02-15
WO2000037638A3 (fr) 2000-11-09
KR100499600B1 (ko) 2005-07-07
PT1484338E (pt) 2007-05-31
JP2007291116A (ja) 2007-11-08
DK1484338T3 (da) 2007-06-11
IL186153A0 (en) 2008-01-20
DE69935085D1 (de) 2007-03-22
JP3993746B2 (ja) 2007-10-17
MXPA01006330A (es) 2002-07-02
KR20010084882A (ko) 2001-09-06
AU768230B2 (en) 2003-12-04
ES2281704T3 (es) 2007-10-01
ATE432987T1 (de) 2009-06-15
DE69935085T2 (de) 2007-08-23
JP2003529317A (ja) 2003-10-07
JP2005237383A (ja) 2005-09-08
JP2005245451A (ja) 2005-09-15
DE69940964D1 (de) 2009-07-16
JP2007222180A (ja) 2007-09-06

Similar Documents

Publication Publication Date Title
AU768230B2 (en) Methods and compositions for inhibiting neoplastic cell growth
WO2000073348A2 (fr) Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
WO2000075327A1 (fr) Methodes et compositions d'inhibition de croissance cellulaire neoplasique
WO2000053752A2 (fr) Activation ou inhibition de l'angiogenese et de la cardiovascularisation
ZA200103885B (en) Methods and compositions for inhibiting neoplastic cell growth.
EP1135491A2 (fr) Methodes et compositions permettant d'inhiber la croissance de cellules neoplasiques
US20020010137A1 (en) Methods and compositions for inhibiting neoplastic cell growth
CA2390685C (fr) Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique
WO2001040464A1 (fr) Kinase 3 associee au recepteur de l'interleukine 1 (irak3) et son utilisation pour stimuler ou inhiber l'angiogenese et la cardiovascularisation
WO2000015797A2 (fr) Compositions et methodes de traitement des maladies relatives au syteme immunitaire
AU758462B2 (en) Methods and compositions for inhibiting neoplastic cell growth
WO2000075316A1 (fr) Procedes et compositions pour l'inhibition de la croissance de cellules neoplastiques
AU2003213166B2 (en) Novel polypeptides having sequence similarity to GDNFR and nucleic acids encoding the same
AU2003257515B2 (en) Methods and compositions for inhibiting neoplastic cell growth
EP1820859B1 (fr) Procédés et compositions d'inhibition de la croissance de cellules néoplasiques
AU2003204815B2 (en) Methods and compositions for inhibiting neoplastic cell growth
WO2000053751A1 (fr) Procedes et compositions pour l'inhibition de la croissance de cellules neoplasiques
EP1466977A1 (fr) Procédés et compositions pour l'inhibition de la croissance de cellules néoplastiques
WO2000055319A1 (fr) Procedes et compositions pour inhiber la croissance des cellules neoplasiques
EP1518930A2 (fr) Procédés et compositions inhibant la croissance des cellules néoplastiques
ZA200103883B (en) Method and compositions for inhibiting neoplastic cell growth.
WO2001019987A1 (fr) Promotion ou inhibition de l'angiogenese et de la vascularisation cardiaque
EP1114154A2 (fr) Compositions et methodes de traitement des maladies relatives au syteme immunitaire

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010611

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20030825

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040505